Published in final edited form as:

J Med Chem. 2011 August 11; 54(15): 5540–5561. doi:10.1021/jm200592f.

Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent *Plasmodium falciparum* dihydroorotate dehydrogenase inhibitors with clinical candidate potential

Jose M. Coteron¹, María Marco¹, Jorge Esquivias¹, Xiaoyi Deng², Karen L. White³, John White⁴, Maria Koltun³, Farah El Mazouni², Sreekanth Kokkonda⁴, Kasiram Katneni³, Ravi Bhamidipati³, David M. Shackleford³, Iñigo Angulo Barturen¹, Santiago B. Ferrer¹, María Belén Jiménez-Díaz¹, Francisco-Javier Gamo¹, Elizabeth J. Goldsmith⁵, William N. Charman³, Ian Bathurst⁶, David Floyd⁶, David Matthews⁶, Jeremy N. Burrows⁶, Pradipsinh K. Rathod⁴, Susan A. Charman³, and Margaret A. Phillips^{2,*}

¹GlaxoSmithKline, Diseases of the Developing World (DDW)-Tres Cantos Medicines Development Campus, Madrid, Spain

²Department of Pharmacology, University of Texas Southwestern Medical Center at Dallas, 6001 Forest Park Rd, Dallas, Texas 75390-9041

³Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus), Parkville, VIC 3052, Australia

⁴Departments of Chemistry and Global Health, University of Washington, Seattle, WA 98195

⁵Department of Biochemistry, University of Texas Southwestern Medical Center at Dallas, 6001 Forest Park Rd, Dallas, Texas 75390-9041

⁶Medicines for Malaria Venture, Geneva

Abstract

Drug therapy is the mainstay of antimalarial therapy, yet current drugs are threatened by the development of resistance. In an effort to identify new potential anti-malarials we have undertaken a lead optimization program around our previously identified triazolopyrimidine-based series of *Plasmodium falciparum* dihydroorotate dehydrogenase (*Pf*DHODH) inhibitors. The X-ray structure of *Pf*DHODH was used to inform the medicinal chemistry program allowing the identification of a potent and selective inhibitor (**DSM265**) that acts through DHODH inhibition to kill both sensitive and drug resistant strains of the parasite. This compound has similar potency to chloroquine in the humanized SCID mouse *P. falciparum* model, can be synthesized by a simple route, and rodent pharmacokinetic studies demonstrated it has excellent oral bioavailability, a long half-life and low clearance. These studies have identified the first candidate in the triazolopyrimidine series to meet previously established progression criteria for efficacy and ADME properties, justifying further development of this compound towards clinical candidate status.

* Author to whom all correspondence should be addressed. Tel: (214) 645-6164. margaret.phillips@UTSouthwestern.edu.

The X-ray structure coordinates for *Pf*DHODH in complex with **37** have been deposited in the Protein data bank as PDB ID code 3SFK.

Supplemental Materials. A table of synthetic intermediates (Table S1), a table of the crystallographic refinement statistics (Table S2) and figure of the Fo-Fc difference map (Figure S1) are included as supplemental material.

Introduction

Malaria is an ancient human enemy with descriptions of malarial-like febrile illness documented over two thousand years ago in the writings of the Greek physician Hippocrates.¹ The identification of the parasite and the link to mosquito-based transmission in 1880 led to our modern understanding of the disease. Drugs to treat malaria predate our knowledge of its etiology (e.g. quinine was isolated from the cinchona bark in 1820), yet today malaria still leads to 220 million cases and approximately 1 million deaths per year, with over 2 billion people at risk for the disease.^{2, 3} The world community is currently involved in its second attempt at global malaria eradication.⁴ While some progress has been made in developing a vaccine, the best candidate RTSS provides only partial immunity.⁵ Thus the mainstay of anti-malarial treatment, and the key to successful eradication continues to be chemotherapy. Against a backdrop of widespread drug resistance to traditional therapies (e.g. chloroquine and pyrimethamine/sulfadoxine), the introduction of artemisinin-based combination therapies (ACTs) has become the most powerful tool to combat the disease.^{6, 7} ACTs are highly effective for the treatment of *Plasmodium falciparum* malaria leading to significant reduction in the mortality and morbidity of the disease. Recent emergence of potential artemisinin resistance along the Thai-Cambodia border threatens to derail these successes, as well as any hope at global eradication.⁸ Few clinically approved treatment options will remain if artemisinin resistance becomes widespread.

A continual pipeline to identify and develop anti-malarial agents is required to combat the ability of the parasite to rapidly acquire resistance to chemotherapy in the field.⁹ The global effort to identify new drugs is being fueled by not-for-profit organizations and the development of substantial portfolios of candidate molecules ranging from identified hits to compounds in clinical development.^{10–12} The completion of whole organism screens of large chemical libraries has identified thousands of new chemical species with anti-malarial activity^{13, 14}, while target-based approaches are also being successfully used to find novel chemotypes. The translation of these findings to clinical successes still presents a formidable challenge to the development of new drugs.

Dihydroorotate dehydrogenase (DHODH) has emerged as the best validated new target for the development of novel anti-malarials since the identification of the bc1 complex as the target of atovaquone, based on the discovery of several classes of inhibitors with anti-malarial activity.¹⁵ DHODH catalyses the fourth step in the de novo pyrimidine biosynthetic pathway, the flavin mononucleotide (FMN)-dependent oxidation of dihydrorotate to orotic acid. *P. falciparum* DHODH (*Pf*DHODH) is localized to the inner mitochondrial-membrane and utilizes ubiquinone (CoQ) as the final electron acceptor to regenerate oxidized FMN. The malaria parasite is uniquely vulnerable to inhibition of this pathway because it lacks the salvage enzymes that serve as an additional source of pyrimidine nucleosides in other organisms, including the human host. Several different chemical series that are potent inhibitors of *Pf*DHODH have been identified by enzyme activity-based HTS and were subsequently found to have anti-malarial activity both *in vitro* and *in vivo*. These include the triazolopyrimidines (**1**) (Fig. 1) identified by our group^{16–19} and N-alkyl-5-(1H-benzimidazol-1-yl)thiophene-2-carboxamides identified by Genzyme and colleagues.^{20, 21} Structural analysis of the bound inhibitor enzyme complexes has revealed that these different chemical classes have overlapping but distinctly different binding modes owing to conformational flexibility in the enzyme inhibitor binding-site.^{21, 22} Most recently, metabolically stable triazolopyrimidines (**2 – 4**)(Fig. 1) have been identified that are able to suppress parasites in a mouse model of infection, however these compounds lacked the potency required in a clinical development candidate.^{16, 19} In order to improve the potency of the series, we have utilized the X-ray structural information to guide additional medicinal chemistry. The enzyme bound structure of **1** and **2** showed that the triazolopyrimidines filled

most of the available binding pocket, but that a channel between the C2 position of the triazolopyrimidine ring and the FMN cofactor was available that could potentially accommodate additional functionality.²² In a major advance forward, herein we describe the lead optimization program to modify the C2 position of the triazolopyrimidine scaffold that has yielded several potent compounds with pharmacokinetic profiles and *in vivo* efficacy in mouse models that meet previously established progression criteria.

Chemistry

The focus of this study was to examine the SAR associated with modifications of the substituent at C2 of the triazolopyrimidine ring system. The development of a synthetic strategy for these triazolopyrimidine derivatives was dictated by the nature of the atom used as linker at the C2- position of the ring. The synthesis of the 2-substituted analogs **11–55** shown in Table 1 proceeded through the intermediate 7-hydroxy-triazolopyrimidines **9** shown in Scheme 1, which was accessed by two routes. The most general approach involved the condensation of ethyl 3-oxobutanoate with aminoguanidine hydrochloride to afford diaminopyrimidone **7** in moderate yield (**11–42** and **45–55**). This route had the advantage that **7** served as a common intermediate from which a diverse set of C2 alkyl analogs could be prepared. Reaction of **7** with a variety of acid chlorides (R defined in Table 1) gave the C2 substituted triazolopyrimidones **9** in good to excellent yields, even with sterically hindered R-groups. This reaction apparently proceeded by initial acylation of **7** followed by a slower cyclization step yielding **9** and, in some cases, required more forcing conditions to effect complete conversion to **9**.²³ Alternatively, to generate **43**, **44** and **100**, we used our previously described chemistry^{16, 17, 19} in which the 5-aminotriazoles **8** were either commercially available or prepared initially (see experimental). In these cases, the reaction of **8** with ethyl 3-oxobutanoate proceeded through the acetoacetate ketone with formation of an aminocrotonate intermediate that cyclizes at the N-2 of the triazole ring yielding the desired isomer **9**.^{24, 25} The limitation of this approach was the availability of starting 3-substituted-5-amino-1,2,4-triazole derivatives due to lengthy reaction times, inefficiency and variable results during their preparation. Treatment of **9** with phosphoryl chloride then gave the chloro triazolopyrimidines **10**, which could be converted to the desired 2-substituted 7-aminoaryl products **11–55**, **100** by reaction with the requisite aniline under a variety of conditions.

As shown in Scheme 2, the preparation of analogs with either S- or O-linked substituents at C2 (**58–84**) started with the commercially available triazolopyrimidone **56**. Conversion of **56** to the chloride (**57**, R = SMe) under the standard conditions followed by displacement of the chloro group with the requisite aniline afforded compounds **58–61** in good yields. Oxidation with hydrogen peroxide in the presence of catalytic Na₂WO₄ in hot aqueous acetic acid proved to be very straight forward, although competitive nitrogen oxidation lowered the yield of this step. Nevertheless, compounds **62–65** were easily prepared by this procedure. These compounds then served as intermediates for the preparation of compounds **66–84** by taking advantage of the methylsulfonyl group to act as a leaving group. Thus, treatment of these C2 methylsulfonyl analogs with a variety of alkyl and functionalized alkyl alkoxides under microwave conditions afforded the desired compounds (**66–84**) in good yields.

Analogues with amino (**89–97**) or hydroxyl (**98**, **99**, **101**) functionality at the R position were obtained from specific intermediates **45 – 47** (prepared as in Scheme 1) and further derivatized as shown in Schemes 3 and 4. Compounds **89–97** were generated in moderate to good yields by treating the fully elaborated chloromethyl (**45a**, **45b**) or chloroethyl (**46a**, **46b**) analogs with the appropriate amine in methanol or THF in the microwave at 120°C (Scheme 3). The hydroxy alkyl analogs **98–99**, **101** were prepared by hydrogenolysis

(Scheme 4) of the requisite benzyl ether (**47a**, **47b**) using flow chemistry with an H-cube instrument.

Results

Optimization of inhibitor potency

The original triazolopyrimidine lead compound (**1**) was identified by HTS in a *Pf*DHODH-based enzyme activity based screen.¹⁷ This compound was a potent and selective inhibitor of *Pf*DHODH, however it was rapidly metabolized and showed no activity against the parasite *in vivo*. Replacement of the naphthyl amine with para-substituted anilines led to the identification of metabolically stable analogs (e.g. **2** – **4**) that were able to suppress parasite growth in the *P. berghei* mouse model^{16, 19} (Figure 1). Additionally these studies identified the key anilines (4-CF₃ and 4-SF₅) that provided the optimal balance between parasite activity and metabolic stability. These compounds (**2** – **4**) however were less potent than expected of a drug candidate and required large doses for *in vivo* efficacy. The X-ray structures of *Pf*DHODH bound to **1** and **2** were determined and this analysis identified a narrow channel leading from the C2 carbon of the triazolopyrimidine ring towards the bound FMN cofactor.²² This channel is lined by several hydrophobic side chains, the aliphatic side chain portion of Arg265 and by a single polar group – the side chain hydroxyl of Tyr528. This hydroxyl donates a hydrogen bond to the carbonyl oxygen of Gly226. In the co-crystal structure of *Pf*DHODH with **1**, but not with **2**, a single ordered water molecule is trapped between bound inhibitor and protein on one side of the channel where it donates hydrogen bonds to the hydroxyl of Tyr528 and to N1 of **1**. The crystal structures indicate that the triazolopyrimidine in **2** penetrates about 0.3 Å more deeply into the narrow channel than is the case with **1** which may force a slight movement of the water molecule destabilizing its hydrogen bonding interactions and disordering its binding. In order to improve the potency of the compound series, we sought to exploit potential additional binding energy by building functionality from the C2 position of the ring. We reasoned that an unbranched alkyl substituent at C2 would fit well into the allowed space in the pocket. But we also recognized that protein conformational changes seen previously in *Pf*DHODH as a response to binding different inhibitor chemotypes²² could possibly alter the shape and electronic characteristics of this narrow channel if probed by suitable C2 substituents.

In order to identify the most active and promising compound, we undertook a systematic evaluation of modification of the triazolopyrimidine ring at the C2 position including some larger and more polar substituents that were designed to probe the sensitivity of the channel to possible ligand induced conformational changes. The chemistry was designed to allow study of different structural effects including chain length effects, branch-group effects at different distances in C2, electronic effects on the 5-member ring of the triazolopyrimidine, heteroatom effects at different distances in C2, polarity effects at different distances in C2 or donor- and acceptor- hydrogen-bonding effects in C2 looking for an extra interaction with the FMN co-factor. In order to evaluate whether the previously optimized anilines (4-CF₃ and 4-SF₅) remained appropriate for the various functional groups that were coupled to C2, four different anilines (4-Cl, 3-Cl, 4-CF₃ and 4-SF₅) were tested within each series.

Compounds were initially evaluated for potency against *Pf*DHODH and against the *P. falciparum* parasite in whole cell assays (Tables 1). Generally we observed a good correspondence between activity against *Pf*DHODH and inhibition of *P. falciparum* 3D7 cell growth for the compounds in the series. Alkyl R-groups at C2 were tested to explore the size of the pocket, including ethyl (**11** – **14**), iso-propyl (**15** – **18**), iso-butyl (**19**–**22**), tert-butyl (**23** and **24**), sec-butyl (**25** and **26**), and cyclopropyl (**27** – **30**). All but the iso-butyl substituents were tolerated and had similar activity to the parent compounds (**2** – **6**), with a small (2 – 3-fold) improvement in potency against *Pf*DHODH observed for **13**, **17** and **29**, or

a larger 5 – 10 fold improvement observed for the 3-Cl aniline (**12** and **16**) or the 4-Cl aniline (**11** and **15**) derivatives. These data suggest the geometry of the channel is wide enough to accept steric hindrance on the atom adjacent to the C2 carbon of the triazolopyrimidine ring but that it narrows beyond the second atom from C2. Compounds with a direct ether linkage to the triazolopyrimidine ring, OMe (**66** and **67**) and OEt (**68** – **71**), also showed similar to modestly improved potency when compared to the parent compounds (**2** – **6**). In the context of 4-CF₃ or 4-SF₅ –aniline, the addition of OEt at C2 (**70** and **71**) led to 4–8-fold improved potency against *Pf*DHODH, however both were less active than those containing a haloalkyl (**37** and **38**). Addition of a linker carbon between C2 and cyclopropyl (**31** – **34**) led to reduced inhibitory activity as did increasing the chain length of the ethyl ether group at C2 (-OCH₂CH₂OCH₃) (**72** and **73**), demonstrating that the pocket is not able to accommodate these larger groups at the C2 position. Compounds that contained an ether linkage in the R group (**48** – **55**) that were not directly linked to the triazolopyrimidine ring showed in general lower activity than the parent compounds (**2** – **6**), as did those containing an alcohol (-CH₂OH (**98**, **99**) or -CH₂CH₂OH (**101**)). Addition of an amine functionality into the R at C2 (**74** – **84**, **89** – **97**) led to complete loss in inhibitory activity independent of the substitution pattern on the N atom or its position in the chain, thus confirming the lipophilic character of the channel. Transformation of C2 into a carbonyl moiety (**85** and **86**) also led to complete loss in inhibitory activity.

The most potent inhibitory activity against *Pf*DHODH was from compounds that contained an unbranched haloalkyl R group at C2, including -CF₂CH₃ (**35** – **38**), -CF₂CH₂CH₃ (**39** – **42**) or -CF₃ (**43** and **44**), an unbranched alkyl sulfur or oxygen containing group like -SCH₃ (**58** – **61**) or -SO₂CH₃ (**62** – **65**). Of these compounds, **37** (4-CF₃-aniline), **60** (4-CF₃-aniline) and **38** (4-SF₅-aniline) demonstrated the best potency against the parasite in whole cell assays (EC₅₀'s below 20 nM against *P. falciparum* 3D7). For **35** – **38**, the addition of CF₂CH₃ to the C2 position improved activity by 4–40-fold against *Pf*DHODH and of 25–240-fold against the parasite compared to the matched analogs (**2** – **6**) containing a hydrogen at C2 (Figure 2). A similar improvement in potency was observed for addition of SCH₃ at C2 (**60**). Compounds containing 4-Cl (**35**, **39**) or 3-Cl (**36**, **40**) aniline showed greater fold improvement in potency against *Pf*DHODH than the 4-CF₃ (**37**) and 4-SF₅ (**38**) anilines, but the larger fold improvement has its origin in the poorer activity of the parent chloro compounds (R = H, **5** and **6**), and the absolute potency of these compounds against *Pf*DHODH is similar to those with 4-CF₃ and 4-SF₅ aniline.

Compounds **37** and **38** were also tested for whole cell activity in media supplemented with Albumax instead of human serum because we previously observed these two media gave different results for compounds containing the 4-SF₅ aniline.¹⁹ As observed for compound **3**, compound **38** also showed 6–7-fold better activity against parasites cultured in media supplemented with Albumax in comparison to human serum, whereas for **37** results were similar in the two media (Table 1).

Physicochemical properties and plasma protein binding

A selection of compounds were chosen for analysis of their physicochemical properties including LogD, aqueous solubility and plasma protein binding (Table 2). The compounds in the series all have physicochemical properties that are consistent with good oral absorption (MW <430, H bond donors <2 and H bond acceptors <6, polar surface area < 90 Å²). The LogD for the series of compounds was found to range from 2.8 – 3.9 and was typically highest for compounds containing a 4-SF₅ aniline. Aqueous solubility varied from poor to good, and compounds with 4-SF₅ aniline were the least soluble while those with 3- or 4-Cl aniline were among the best. The most potent compounds (**37** and **38**) showed mid range solubility and again, the 4-SF₅ aniline (30 – 60 μM) derivative was less soluble than the 4-CF₃ aniline (70 – 140 μM). Human plasma protein binding was evaluated by two

methods: 1) a chromatographic method that allowed rapid evaluation of a larger number of compounds and was useful for comparative purposes, and 2) a more rigorous ultracentrifugation method that provided an accurate absolute value for assessing total versus free drug concentrations in the *in vivo* models. Using the chromatographic method, compounds in the series typically ranged from 85 – 98% protein bound, with those containing the 4-SF₅ aniline having both the highest LogD and the highest plasma protein binding. For those compounds (**37** and **38**) that were evaluated with both methods, the ultracentrifugation method yielded a higher protein binding value than the chromatographic method. Protein binding for **38** was found to be very high in both human and mouse plasma (99.9 and 99.6%, respectively), whereas the binding of **37** was somewhat lower (98.8 and 97.4%, respectively). For both **37** and **38**, protein binding in rat plasma (94.2 and 97.3%, respectively) was lower than that in either mouse or human plasma, but the binding of **38** was still higher than that of **37**. Protein binding in the Albumax media used for *in vitro* activity assessment was not measured but it is likely that the intrinsic “free” *in vitro* potency of compound **38** is extremely high.

In vitro metabolic stability

As an initial screen for good *in vivo* pharmacokinetic properties, metabolic stability was evaluated *in vitro* using human and mouse hepatic microsomes. We have previously observed a good correlation between stability in microsomal assays and exposure in rodents for the triazolopyrimidine series^{16, 19}. In this assay, *in vitro* intrinsic clearance (CL_{int}) values were measured and used to predict an *in vivo* intrinsic clearance and subsequently, an *in vivo* hepatic extraction ratio (E_h) (fraction of compound predicted to be metabolized on the first pass through the liver) with the assumption that hepatic metabolism would represent the primary clearance mechanism. Compounds that contained - CF₂CH₃ (**37** – **38**), - CF₂CH₂CH₃ (**41** – **42**), or -CF₃ (**43** – **44**) at the C2 position showed low intrinsic clearance (CL_{int} <6 μL/min/mg microsomal protein in human microsomes and <10 μL/min/mg in mouse microsomes) in these assays, provided that these C2 R groups were coupled with the 4-CF₃ (**37**, **41**, **43**) or 4-SF₅ (**38**, **42**, **44**) aniline (Table 2). The low intrinsic clearance values suggested that these compounds would exhibit good metabolic stability in both mice and humans. Compounds containing 4- Cl (**11**, **35**) or 3-Cl (**12**, **36**) aniline had much higher intrinsic clearance values suggesting that they would be more rapidly metabolized *in vivo*. Compounds containing an -CH₂CH₃ (**13** and **14**), an - OCH₂CH₃ (**70** and **71**), -cyclopropyl (**29** and **30**), -CH₂OCH₃ (**50** and **51**), -CH₂CH₂OCH₃ (**54** and **55**) or -CH₂CH₂OH (**101**) at C2 also showed good metabolic stability, again provided that these C2 R groups were coupled to either 4-CF₃ or 4-SF₅ rather than to 3- or 4-Cl aniline. However, these compounds were all less potent than those containing a haloalkyl (**37** and **38**) group. Compounds that contained sulfur (**60** and **61**) were among the most potent PfDHODH inhibitors in the series, however they showed poor metabolic stability and were therefore not likely to show sufficient exposure *in vivo* to provide efficacy. Thus, the compounds that provided the best balance between potency and metabolic stability were identified to be **37** and **38**, and these were selected as the front-runners for further characterization.

Species selectivity and evaluation of cytotoxicity

Select compounds were evaluated for activity against *P. berghei*, *P. vivax* and human DHODH (Table 1). The addition of groups larger than hydrogen at C2 systematically reduced binding affinity to the *P. berghei* enzyme; for example, **37** and **38** were 100-fold less potent on *P. berghei* DHODH than on the *P. falciparum* enzyme. In contrast to the results on PfDHODH, *P. vivax* DHODH was inhibited with similar potency to PfDHODH by both **37** and **38** (*P. vivax* DHODH IC₅₀ = 0.084 and 0.073 μM, respectively), suggesting that both compounds will have good activity against *P. vivax* parasites. Compounds in the series continued to show excellent selectivity against the human enzyme, and the IC₅₀ for

*h*DHODH was >100 μ M (Table 1) for all of the evaluated compounds with the exception of **44** which showed weak activity against the human enzyme (IC_{50} = 41 μ M).

The two front-runner compounds **37** and **38** were tested against an expanded panel of *P. falciparum* strains (Table 3). Both compounds showed similar potency against drug sensitive and drug resistant (chloroquine and atovaquone) strains. Cytotoxicity was assessed against both a mouse (L1210) and human (HepG2) cell line and no activity within the tested range (up to 50 μ M) was observed for either compound against these cell lines.

Evaluation of the antimalarial mode of action

In order to confirm that cell killing by the DHODH inhibitors results from inhibition of *Pf*DHODH, we tested the inhibitors against a *P. falciparum* D10 cell line transfected with cytoplasmic yeast DHODH (D10_yDHODH) that uses fumarate instead of mitochondrial CoQ as the final electron acceptor.²⁶ This cell line has previously been demonstrated to rescue parasites from the toxicity of both, mitochondrial bc1 complex inhibitors such as atovaquone²⁶ and *Pf*DHODH inhibitors such as our triazolopyrimidines.^{13, 27} Addition of proguanil has been shown to restore sensitivity of D10_yDHODH to bc1 complex inhibitors but not to specific *Pf*DHODH inhibitors. The D10_yDHODH cell line is resistant to both **37** and **38** and this result was independent of the presence of proguanil in the culture media, demonstrating that the antimalarial effect of these compounds is due to inhibition of *Pf*DHODH. Representative data for **38** are shown in Fig. 2.

X-ray structure determination of *Pf*DHODH in complex with **37**

The X-ray structure of *Pf*DHODH in complex with **37** was solved to 2.95 Å resolution (Table S1; Fig. S1 supplemental). Both the triazolopyrimidine ring and the aniline ring superimpose closely onto the position of **2** (pdb 3I6R)²² though there is a slight shift of both rings away from FMN and towards Phe188 (RMSD = 0.4Å)(Fig. 3A). The key interactions are preserved, including an H-bond between His185 and the pendant nitrogen that bridges between the triazolopyrimidine ring and the phenyl ring, and an H-bond between Arg265 and the pyrimidine nitrogen N4. The CF₂CH₃ R-substituent of **37** binds into the channel that extends from the triazolopyrimidine ring towards the FMN and makes good van der Waals interactions throughout the pocket, which is composed of Ile263, Ile272, the hydrophobic portion of the Arg265 side chain, and of the hydroxyl and ring of Tyr528 (Fig. 3B). Thus the addition of the -CF₂CH₃ R-substituent to the scaffold provides key hydrophobic interactions with the enzyme in the one significant space that was left unoccupied by the previous analogs from the series. Furthermore the electron withdrawing effect of the fluorine atoms will reduce electron density on the nitrogens within the 5-membered triazole ring. This may, therefore, contribute to the potency increase as a result of decreased desolvation. These observations provide a structural explanation for the improved potency of these analogs. The structure also provides insight as to why R groups that are larger than propyl are inactive (e.g. **19** – **22**) as the pocket has insufficient room to accommodate a branched chain functionality as large as iso-butyl. The complete inactivity of R groups containing an amine functionality is explained by the hydrophobicity of the R-pocket and the lack of H-bonding partners in the R-pocket except for lone pair electrons of the Tyr528 side chain hydroxyl. Finally, the X-ray structure provides insight into the poor binding of **37** to *Pb*DHODH. The replacement of Gly181 with Ser in *Pb*DHODH may lead to a restriction in the size of the R-group that can be accommodated by this enzyme.

Pharmacokinetic properties in mice and rats

To further assess the potential for **37** and **38** to be selected as clinical development candidates, their pharmacokinetic properties were assessed in mice and rats. In non-infected mice, **37** and **38** showed good exposure following single dose oral administration (Fig. 4 and

Table 4B). Maximum plasma concentrations ($C_{\max}$) and $AUC_{0-\infty}$ values of **38** increased approximately in proportion to the increase in dose over the range 0.4 – 10 mg/kg range, however the relative increase was somewhat reduced at 50 mg/kg dose. Compound **37** exhibited dose proportional increases in $C_{\max}$ and $AUC_{0-\infty}$ across the full dose range (0.4 – 50 mg/kg). Four other compounds (**13**, **41**, **70** and **71**) with good potency ($EC_{50} < 0.1 \mu\text{M}$) against the parasite and good metabolic stability were also tested to evaluate plasma exposure in mice (Table 4B). Compounds **13** and **70** showed similar exposure to **37** and **38** as evaluated by both $C_{\max}$ and $AUC_{0-\infty}$, while compounds **41** and **71** had somewhat lower exposure.

The pharmacokinetic properties of **37** and **38** in rats were examined after both intravenous (i.v.) and oral (p.o.) administration. After i.v. dosing, **38** had low clearance (4–6 mL/min/kg), moderately high volume of distribution (3–6 L/kg), and a long half-life (10–13 h) whereas **37** exhibited higher clearance (13–23 mL/min/kg), similar volume of distribution (3 L/kg), and a shorter half-life (4–6 h). Neither compound was excreted unchanged in urine. After oral dosing, both **37** and **38** demonstrated good oral bioavailability and long half-lives (Table 5 and Fig. 5), however the increase in both the time to reach the maximum concentration ($T_{\max}$) and the half-life with increasing dose suggested a slower rate of absorption with increasing dose. Compound **38** showed dose-proportional kinetics over the oral dose range of 2–50 mg/kg while for **37**, there was evidence for dose-dependency over the range of 2–20 mg/kg.

In vivo efficacy of **37** and **38** in the *P. falciparum* SCID mouse model

The observation of good bioavailability of **37** and **38** in mice and rats led us to test these compounds in an *in vivo* efficacy model. The poor activity of **37** and **38** against *PbDHODH* prohibited the use of the *P. berghei* mouse model to evaluate their *in vivo* efficacy. To overcome this issue, **37** and **38** were tested against the human malaria parasite *P. falciparum* in the humanized SCID mouse model.²⁸ To provide a direct comparator to our prior studies that used the *P. berghei* mouse model, compound **4** (*in vivo* mouse *P. berghei* $ED_{50} = 10$ mg/kg for **4**)¹⁹, was included in the SCID mouse study. Unlike **37** and **38**, **4** has similar activity against *PfDHODH* and *PbDHODH*, thus was able to be evaluated in both the SCID mouse and the *P. berghei* mouse models. Chloroquine was also included as a control to represent a standard anti-malarial agent with known behavior in the SCID mouse model.

Compounds (**4**, **37** and **38**) were dosed orally 1× daily for 4 days beginning 3 days after mice were infected with parasites. The ED_{50} 's were determined 24 h after the final dose as described.²⁸ Both **37** and **38** markedly inhibited parasitemia in peripheral blood of mice ($ED_{90} = 25.9$ mg/kg and 8.1 mg/kg, respectively), with **38** showing efficacy at doses in the order of chloroquine ($ED_{90} = 4.9 \pm 0.5$ mg/kg) and artesunate (12.7 ± 1.3 mg/kg)²⁸ (Table 6 and Fig. 6). Compound **38** has a clear potency advantage over **37**, however both were more potent than **4** (by 7-fold and 2-fold respectively) and both meet our development criteria for a preclinical candidate (defined as an $ED_{90} < 30$ mg/kg in this model). Interestingly, aberrant late trophozoites/early schizonts were detected in peripheral blood of mice treated effectively with compounds **37** and **38**, which is consistent with a mechanism of action affecting parasite metabolism. The comparator compound **4**, showed similar efficacy in the SCID model ($ED_{50} = 19$ mg/kg) to what was observed previously in the *P. berghei* model ($ED_{50} = 10$ mg/kg)¹⁹.

A pharmacokinetic study in uninfected and infected SCID mice engrafted with human erythrocytes was performed in order to interpret the efficacy results. The oral exposure of **4**, **37**, and **38** upon p.o. administration at 10 mg/kg indicated that infection did not significantly change compound disposition of compounds (Table 6). Interestingly, the overall exposure in whole blood for the three compounds studied was similar, which suggest that differences in

intrinsic potency rather than changes in pharmacokinetic parameters are most likely responsible for the differences in efficacy detected *in vivo*.

Discussion

The burden of malaria falls disproportionately on the world's poorest countries and while effective treatments are in place, the continual challenge is to stay ahead of the parasite's unyielding ability to select for drug resistance. The identification of new chemical classes with different modes of action than existing drugs, and which also show good drug-like properties and efficacy against the parasite is the key to treatment of the disease. Through a structure-guided lead optimization program that integrated pharmacokinetic and metabolism assessment into the medicinal chemistry plan, we have identified two potent *Pf*DHODH inhibitors (**37** and **38**) from the triazolopyrimidine series that meet previously established progression criteria. The antiparasitic activity of these compounds in the humanized SCID mouse *P. falciparum* model ($ED_{90} < 30$ mg/kg) suggests that both compounds show good *in vivo* efficacy. Parallel pharmacokinetic studies in mice and rats demonstrated sustained plasma concentrations after oral dosing consistent with once daily dosing, and both compounds are active against drug sensitive and drug resistant strains of the parasite, all of which are necessary to meet the target product profile.¹¹ These compounds represent a significant breakthrough in potency compared to previously identified compounds from this series, and they represent the first that are potent enough to be progressed for clinical development.

The triazolopyrimidines were identified early in our program to develop *Pf*DHODH inhibitors for the treatment of malaria, however previous compounds from the series have either lacked metabolic stability (**1**) or have shown insufficient potency against the parasite (**2** – **4**).^{16, 17, 19} The X-ray structure of **1** and **2** bound to *Pf*DHODH showed that a narrow channel leading from the C2 position of the triazolopyrimidine ring towards the FMN cofactor afforded the best chance to build additional functionality into the molecule to improve potency.²² We have systematically evaluated a series of alkyl, haloalkyl, ether and amine substituents in this position leading to the identification of several functional groups that provided the desired boost in potency. Most of the best functional groups at C2 are electron withdrawing and hydrophobic, and the rank order of potency against both the enzyme and the parasite in whole cell assays was $-\text{CF}_2\text{CH}_3$, $-\text{SCH}_3 > -\text{CF}_3$, $-\text{CF}_2\text{CH}_2\text{CH}_3 > -\text{OCH}_2\text{CH}_2 > -\text{CH}_2\text{CH}_3$. Larger substituents and branched chain or cyclic groups were less active. These results match well with the observation from the X-ray structure of **37** bound to *Pf*DHODH, which shows that the C2 binding pocket is narrow and dominated by hydrophobic residues. As was observed in prior compounds that contain hydrogen at the C2 position¹⁹, anilines substituted with 4- CF_3 or 4- SF_5 provided the best balance between potency and good metabolic stability. Compounds with 4-Cl or 3-Cl showed somewhat lower potency and were notably less metabolically stable.

In contrast to the good activity of the haloalkyl substituents, all compounds containing amines at C2 were inactive. The X-ray structure analysis shows that except for the hydroxyl oxygen of Tyr528, there are no H bond acceptors in the pocket that would bind a C2 substituent. In the absence of a major ligand induced reorganization of the pocket, the Tyr528 side chain oxygen is geometrically inaccessible to any potential hydrogen bonding group such as an amine directly linked through a tetrahedral carbon attached to the triazolopyrimidine at C2. The addition of alcohols at C2 also led to reduced activity. These compounds (particularly $-\text{CH}_2\text{CH}_2\text{OH}$ at C2) were designed to displace the bound water molecule (W15) observed to bind between the Tyr528 hydroxyl and N3 on the triazolopyrimidine in the X-ray structure of *Pf*DHODH bound to **1**²², and to test the hypothesis that the resulting gain in entropy would improve binding affinity. However,

compounds with -CH₂OH (**98** and **99**) and -CH₂CH₂OH (**101**) at C2 were less active than the parent compounds **2**, **5** and **6**, suggesting that even if the bound water was displaced, this mechanism did not provide additional binding energy possibly owing to the energetic cost of desolvating the hydroxyl of **101** upon binding to *Pf*DHODH.

The most potent of the analogs with -CF₂CH₃ at C2 (**37** and **38**) were identified as the front-runners and evaluated in a series of additional assays to determine their development potential. These compounds showed 25–50-fold better activity against *P. falciparum* 3D7 cells in whole cell assays than compounds containing hydrogen at C2. This improvement in potency was achieved while remaining on target, as parasites transfected with yeast DHODH were resistant to both inhibitors as would be expected if the cell killing occurred via DHODH inhibition. Both compounds also showed good activity against *Pv*DHODH, suggesting that they will also be useful to treat *P. vivax* infections, and both were fully active against drug resistant strains of the parasite, including atovaquone and chloroquine resistant strains.

Compounds **37** and **38** exhibited good metabolic stability when evaluated in hepatic microsomal assays, and pharmacokinetic profiles confirmed low clearance and good oral bioavailability in both mice and rats leading to high and extended plasma exposure profiles. In rats, compound **37** showed significant dose dependency in the kinetic profile even over a relatively low dose range. The greater than proportional increase in AUC_{0-inf} for **37**, and the corresponding apparent bioavailability of >100% at the higher dose, suggested saturation of the clearance pathway(s) with increasing dose for this compound. In comparison, **38** exhibited reasonably dose proportional kinetics in rats over a broad dose range. The delay in T_{max} and prolongation of the half-life with increasing dose for both **37** and **38** suggests a dose-dependent reduction in the rate of absorption, possibly due to dissolution rate-limited absorption resulting from the relatively low aqueous solubility (Table 2). Importantly, the low solubility did not appear to limit the extent of absorption based on the high bioavailability for both compounds.

Compounds **37** and **38** required a significantly lower dose to clear parasites in a SCID mouse model than prior compounds from the triazolopyrimidine series, and this finding can be attributed to the combination of the significantly improved potency and the good plasma exposure profile. For **38**, the dose required (ED₅₀/ED₉₀ 2.8/8.1 mg/kg) was similar to that for chloroquine examined in the same study, and these values were 7-fold lower than for the previous most efficacious compound from the series (**4**) when tested in the same SCID mouse model. The matched analog of **38** containing a hydrogen at C2 (**3**) has not been tested in this model. However because **3** and **4** have similar activity against *Pb*DHODH and *Pf*DHODH they were both previously tested for efficacy in the *P. berghei* mouse model.¹⁹ In this experiment the ED₅₀ for **3** was 2-fold higher than for **4**, suggesting that the addition of the CF₂CH₃ group to C2 may have improved *in vivo* efficacy by up to 14-fold (e.g. **38** was 7-fold more potent than **4** in the SCID model, and **4** is 2-fold more potent than **3** in the *P. berghei* model). These data also differentiate these compounds from the reported N-alkyl-5-(1H-benzimidazol-1-yl)thiophene-2-carboxamides where the ED₅₀ in the *P. berghei* *in vivo* model for the most potent of these compounds (Genz-667348) was 2–6-fold higher (depending on the parasite strain) and required BID dosing²¹, in comparison to the results obtained for **38** where QD dosing was used.

Results for the plasma protein binding studies with **37** and **38** indicate that the binding of **38** was higher than that of **37** in each of the species tested (e.g. human, rat and mouse), meaning that the free fraction of **38** would be lower than that of **37**. While binding in the Albumax media used for the *in vitro* cell-based assay has not been assessed, the plasma protein binding trends would suggest that **38** would also exhibit higher binding, and lower free

concentrations, in the Albumax media. Since **37** and **38** had similar activity in the *P. falciparum* cell-based assay, a lower free fraction for **38** may indicate that it is actually more potent than **37** if the free concentrations are considered. This hypothesis, combined with the longer half-life and more extended exposure profile for **38** measured in normal mice, may explain the difference in potency for the two compounds in the SCID mouse model despite their similar measured whole blood concentrations.

Based on the better *in vivo* efficacy and the observation of more linear pharmacokinetics in rats, **38** has been chosen as the lead compound for further workup towards clinical candidate status. While none of the other compounds with potency in the same range as **37** and **38** ($EC_{50} < 20$ nM in the whole cell *P. falciparum* assay) were metabolically stable, compounds **13** and **70** were the next best compounds with respect to the combination of potency and metabolic stability. Both compounds also showed good exposure after oral dosing in non-infected mice, and thus might serve as backup compounds to the identified front-runner (**38**).

Conclusion

We have identified a compound (**38**) from the triazolopyrimidine series of *Pf*DHODH inhibitors that meets development criteria, showing efficacy against *P. falciparum* *in vivo* in a murine model, activity against drug resistant parasite strains, and activity against *Pv*DHODH. Importantly the excellent *in vivo* efficacy was obtained with QD dosing, attributable to the long half-life and excellent oral exposure, and suggesting that **38** will be able to meet the target product profile of cure in three consecutive daily doses in patients. Final validation of the development potential of **38** will require toxicological studies in animals and the successful clinical proof of concept of a DHODH inhibitor for the treatment of malaria in man.

Materials and Methods

Determination of enzyme inhibition constants

The plasmids used for the *E. coli* expression of His-tagged *Pf*DHODH, *Pb*DHODH, and *h*DHODH have been previously described.^{16–18} The *P. vivax* DHODH expression construct was generated as follows. A 1266-bp DNA fragment of *Pv*DHODH was amplified by PCR from genomic *P. vivax* strain Belem DNA provided by John Barnwell (CDC) using primers 5'-GTA GTA GCT CTA TAC ATG TAT TTC GAG TCC TAC GAC CCC G -3' and 5'-CTC GAG GGC GGC CCG CCG GTG GGC CCG CCC GAC GGC GT -3' and ligated into Zero Blunt TOPO vector (Invitrogen). QuickChange site-directed mutagenesis kit (Stratagene) was used to remove an internal *NdeI* site from *Pv*DHODH using primers 5'-TGT CTA CTC ACA TGA TTT CTC AAA TG-3' and 5'-CAT TTG AGA AAT CAT GTG AGT AGA CA-3'. The resultant clone was used to PCR amplify the *Pv*DHODH region introducing *XhoI* and *NdeI* restriction sites, respectively with primers 5'-TGG AAT TCG CCC TCG AGG GCG GCC CGC CGG-3' and 5'-GTA GTA GCT CTA CAT ATG TAT TTC GAG TCC TAC GAC-3'. This PCR product was ligated into Zero Blunt TOPO vector (Invitrogen) and digested with *XhoI* and *NdeI* to excise the DHODH coding sequence, which was then ligated to pET22b expression vector (Novagen) to generate the C-terminal 6×His-tagged truncated *Pv*DHODH construct used for recombinant protein expression. All four proteins were expressed as soluble truncated proteins in the absence of the N-terminal domain that includes the membrane-spanning region of the protein. Proteins were purified as previously described by Ni^{+2} -agarose chromatography and gel filtration.^{17, 18}

Steady-state kinetic assays to determine the IC_{50} 's for inhibitors were performed as previously described^{17, 18}. Briefly, a dye-based assay that couples the final oxidation of CoQ to the reduction of 2,6-dichloroindophenol (DCIP) was followed at 600 nm ($\epsilon=18.8$

mM⁻¹cm⁻¹). Enzyme stocks were diluted into assay buffer containing 0.1 mM BSA to make a 100× working stock solution, which was kept on ice. Assays were initiated by adding 5 µl of this stock solution to 500 µl assay buffer containing substrates and inhibitors. Conditions were as follows: DHODH ($E_T = 5 - 10$ nM), substrates (0.2 mM L-dihydroorotate and 0.02 mM CoQ_D), DCIP (0.12 mM) and assay buffer (100 mM HEPES, pH 8.0, 150 mM NaCl, 10% Glycerol, 0.1% Triton) at 20 °C. Inhibitor concentration was varied in a 3-fold dilution series (0.01 – 100 µM). The percent inhibition relative to the no inhibitor control was determined ($v_i/v_o \times 100$) and data were fitted to the log[I] vs response (three parameters) equation in Graph Pad Prism to determine the IC⁵⁰.

X-ray structure determination of PfDHODH Δ 384-413-37

Protein purification. Protein for crystallization was expressed from a different construct than that used for the inhibition studies. Deletion of a surface loop (Δ 384-413) was necessary to generate a protein that could be crystallized, and both the construct and the purification procedure have been previously described.^{21, 22} These prior studies also showed that deletion of this loop had no effect on enzyme activity. Preliminary crystallization conditions were found using the random crystallization screen *AmSO4* suite (Nextal). The initial conditions were refined by variation of pH, precipitant, and protein concentrations to find optimal conditions. Crystallizations were setup using the hanging drop vapor diffusion method at 20°C. Crystals of PfDHODH Δ 384-413-37 complex were obtained by mixing Reservoir solution (1.64 – 1.74 M Ammonium sulfate, 0.1 M Sodium Acetate, pH 4.1, and 10 mM DTT) with an equal volume of PfDHODH Δ 384-413 (20 mg/ml) pre-equilibrated with 0.5 mM 37 and 2 mM dihydroorotate. Crystals typically grew in 4–7 days.

Diffraction data were collected at 100K on beamline 19ID at Advanced Photon Source (APS) using an ADSC Q315 detector. The crystal of PfDHODH Δ 384-413-37 diffracted to 2.95 Å and has a space group of P6₄ with the cell dimension of a=b=86.6, c=138.2. The structure contains only one molecule of PfDHODH in the asymmetric unit. Diffraction data were integrated and intensities were scaled with HKL2000 package²⁹.

Crystallographic phases for PfDHODH inhibitors were solved by molecular replacement with Phaser³⁰ using the previously reported structure of PfDHODH Δ 384-413 (PDB ID 3I65²²) with ligands removed as the search model. Structures were rebuilt with COOT³¹, refined with REFMAC³² to R and R_{free} of 0.236 and 0.285 respectively (Table S2 and Fig. S1, supplemental materials). The final structure contains residues 161–347, 355–383, and 414–565 and 5 water molecules. Electron density was not observed for loop 348–354 is missing. All residues in the final structure were within the allowed section of the Ramachandran plot (Table S2, supplemental materials). Water molecules were added if the density was stronger than 3.4 σ and removed if the density was weaker than 1 σ in the density map with ARP/warp.³³

Molecular Modeling—Structures were displayed using PyMol (DeLano Scientific LLC, San Carlos, CA). The RMSD between the structures of PfDHODH bound to 37 versus 2 was calculated using DaliLite.³⁴

In vitro assay of P. falciparum

Parasites were grown in Gibco-Invitrogen RPMI-1640 supplemented with 20% human type A+ plasma and 2% (w/v) red blood cells³⁵ or with Gibco-Invitrogen 0.5% Albumax I. Before transferring cultures to media with in Albumax, cells were washed three times in RPMI-1640 to remove plasma-supplemented medium. The D10 cell line containing yeast DHODH was cultured in the absence and in the presence of proguanil (5µM). Low-passage L1210 mouse leukemia cells (American Type Culture Collection) were also grown in

plasma-supplemented RPMI-1640, while HepG2 human hepatocarcinoma cells (American Type Culture Collection) were grown in F12/DMEM (1:1). Blood products were obtained from Biochemed Services, Virginia. [³H]-hypoxanthine uptake was used to measure cell growth and incorporation of no-drug samples was compared to drug-treated cells as described previously.³⁶ Data were fitted to the log[I] vs response – variable slope (4 parameter) model in Graph Pad Prism to determine the ED₅₀'s for inhibition of parasite growth.

Physicochemical Properties

Partition coefficients (LogD_{pH 7.4}) were estimated by comparing their chromatographic retention properties to a set of standard compounds with known partition coefficients. Data were collected using a Waters 2795 HPLC instrument with a Waters 2487 dual channel UV detector with a Phenomenex Synergi Hydro-RP 4 μm (30×2 mm) column. The mobile phase was aqueous buffer (50 mM ammonium acetate, pH 7.4) and acetonitrile with an acetonitrile gradient of 0 to 100% over 10 min. Compound elution was monitored at 220 and 254 nm.

Aqueous solubility was estimated by nephelometry. Compound in DMSO was spiked into either pH 6.5 phosphate buffer or 0.01M HCl (approx. pH 2.0) with the final DMSO concentration being 1%. Samples were then analyzed by Nephelometry to determine the solubility range as described previously.³⁷

Plasma protein binding was assessed using two different methods: 1) chromatographic retention on a human albumin column, or 2) ultracentrifugation. The chromatographic method utilized a human albumin column (ChromTech Chiral-HSA 50 × 3.0mm, 5 μm, Sigma-Aldrich) and compared retention characteristics to a series of standard compounds with known human plasma protein binding values using a modification of a published method.³⁸ A Waters 2795 HPLC system equipped with a Waters 2487 dual channel UV detector (monitored at 220 and 254 nm) was used with a mobile phase comprised of aqueous buffer (25 mM ammonium acetate buffer pH 7.4) and 30% isopropanol in the same buffer. The isopropanol concentration was varied over a 10 min gradient and the column was reconditioned prior to the next injection.

Measurement of plasma protein binding by ultracentrifugation was performed using human, rat and mouse plasma. Human blood was obtained from the Australian Red Cross Blood Service), rat blood from male Sprague Dawley rats, and mouse blood from male Swiss outbred mice. Plasma was separated from whole blood by centrifugation and stored frozen at –80°C (human) or –20°C (rat and mouse). Compound stock solutions were prepared in DMSO (1 mg/mL) and then further diluted in 50% (v/v) acetonitrile (20 and 200 μg/mL). Plasma at 37°C was spiked with compound stock solutions to give concentrations of 200 and 2000 ng/mL (maximum final DMSO and acetonitrile concentrations were 0.2% and 0.5%, respectively), followed by equilibration at 37°C for 1 h and ultracentrifugation (Beckman Rotor type 42.2 Ti; 223,000 × g and 37°C) for 4.2 h to separate plasma proteins from plasma-water. An aliquot of supernatant (i.e. plasma-water) was taken from each tube to determine free concentration. The total concentration was determined in non-centrifuged plasma samples similarly incubated. The concentration of test compound in samples was determined by LC-MS using calibration standards prepared in the respective matrices. The percentage of compound bound to plasma proteins (% bound) was calculated according to the following equation: %bound = 100 × (C_{plasma} – C_{plasma-water})/C_{plasma}, where C_{plasma} was the concentration observed in the non-centrifuged plasma 37°C sample and C_{plasma-water} was the plasma-water phase following centrifugation.

In vitro human and mouse metabolism

Human and mouse liver microsomes (BD Gentest, Discovery Labware Inc., Woburn, Massachusetts) were suspended in 0.1 M phosphate buffer (pH 7.4) at a final protein concentration of 0.4 mg/mL and incubated with compounds (1 μ M) at 37°C. An NADPH-regenerating system (1 mg/mL NADP, 1 mg/mL glucose-6-phosphate, 1 U/mL glucose-6-phosphate dehydrogenase) and MgCl₂ (0.67 mg/mL) was added to initiate the metabolic reactions, which were subsequently quenched with ice-cold acetonitrile at time points ranging from 0 – 60 min. Samples were also incubated in the absence of the NADPH-regenerating system to monitor for non-cytochrome P450-mediated metabolism in the microsomal matrix. Samples were then subjected to centrifugation and the amount of parent compound remaining in the supernatant was monitored by LC-MS. The first order rate constant for substrate depletion was determined by fitting the data to an exponential decay function and these values were used to calculate the *in vitro* intrinsic clearance value (CL_{int}) and the predicted *in vivo* intrinsic clearance value (CL_{int vivo}) as described.³⁹ The predicted *in vivo* hepatic extraction ratio (E_h) was calculated using the following relationship: $E_h = CL_{int\ vivo} / (Q + CL_{int\ vivo})$ where Q is liver blood flow (20.7 mL/min/kg, 55.2 mL/min/kg and 90 mL/min/kg in for humans, rats and mice, respectively).⁴⁰

Pharmacokinetic analysis

Animal studies were performed in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes and the study protocol was approved by the Monash Institute of Pharmaceutical Sciences Animal Ethics Committee.

Systemic exposure was studied following oral administration of compounds to non-fasted male Swiss outbred mice after oral administration and to overnight fasted male Sprague Dawley rats after IV and oral administration. Mice were given unrestricted access to food and water throughout the pre- and post-dose phases of the study. Rats were given unrestricted access to water throughout the pre- and post-dose sampling period, and access to food was re-instated 4 h post-dose. For oral dosing, compounds were administered to mice and rats in an aqueous suspension vehicle (0.5% w/v sodium caboxymethylcellulose, 0.5% v/v benzyl alcohol and 0.4% v/v Tween 80; 0.1 mL dose volume per mouse, n=1 mouse per time point; 1.0 mL per rat, n=2 rats per compound) by gavage. After the oral dose was administered to rats, the dosing tube was rinsed with 1 mL of Milli-Q water to collect any residual formulation, and the rinse was also administered. For intravenous dosing to rats, compounds were administered in an aqueous solution vehicle as a 10 min constant rate infusion into the jugular vein at two dose levels (1.0 mL per rat, n=2 rats per dose level for each compound).

At specific time points following oral dosing to mice, animals were anaesthetized with gaseous isoflurane and a single blood sample was collected via cardiac puncture. For sample collection from rats, samples of arterial blood were collected via an in-dwelling carotid cannula. Blood samples collected from mice and rats were immediately transferred to heparinized tubes that contained a stabilization cocktail (Complete[®] inhibitor cocktail, potassium fluoride and EDTA) to minimize the potential for *ex vivo* degradation of the test compound. Plasma for analysis was then collected by centrifugation.

Compound concentrations were quantitated in plasma samples by LC-MS (on either a Micromass Quattro Premier or Micromass Xevo TQ) using calibration standards that were prepared in blank plasma. Plasma samples and standards were prepared by precipitation with acetonitrile, followed by centrifugation and analysis of the supernatant. The analytical lower limit of quantitation (LLQ) value for each compound in plasma was typically 1 ng/mL or below.

Pharmacokinetic parameters were calculated using non-compartmental methods. The terminal elimination half-life ($t_{1/2}$), the area under the plasma concentration versus time profile from time zero to either the last sample time point (AUC_{0-24h}) or extrapolated to infinity (AUC_{0-inf}), plasma clearance, and volume of distribution at steady-state were determined using WinNonlin software (version 5.2.1, Pharsight Corporation, Mountain View, CA). The maximum plasma concentration (C_{max}), the time to reach the maximum concentration (T_{max}) and the time plasma concentrations remained above $1 \mu M$ ($T_{C > 1 \mu M}$) were taken directly from the concentration versus time profiles. Oral bioavailability (%F) was estimated by comparing the average dose-normalized AUC_{0-inf} after oral administration to the average dose-normalized AUC_{0-inf} after IV administration.

P. falciparum in vivo efficacy model and pharmacokinetic analysis

All the experiments were approved by the DDW Ethical Committee on Animal Research, performed at the DDW Laboratory Animal Science facilities accredited by AAALAC, and conducted according to European Union legislation and GlaxoSmithKline policy on the care and use of animals.

Compound efficacy was evaluated against *P. falciparum* Pf3D7^{0087/N9} propagated in NOD-*scid* IL-2R γ^{null} mice that were engrafted with human erythrocytes as previously described.⁴¹ Mice ($n = 3$) were infected on Day 0 with 2×10^7 parasites and compound was administered QD on days 3–6 post infection by oral gavage in an aqueous suspension vehicle (0.5% w/v sodium carboxymethylcellulose, 0.5% v/v benzyl alcohol and 0.4% v/v Tween 80) at 20 ml/kg. Control animals received vehicle alone. ED50 and ED90 were estimated by fitting a 4-decade logistic equation for the $\log_{10}$ of parasitemia at day 7 versus $\log_{10}$ of the dose administered using GraphPad Prism 5.0 (GraphPad Software). Parasitemia was assessed by FACS as previously described.²⁸

In a parallel study, pharmacokinetic properties were also evaluated in the SCID mouse model both in the presence and absence of infection. Compound was administered in a single oral dose of 10 mg/kg and whole blood levels were followed for 24 h. Analytical methods for the detection of compounds **37** and **38** were as described above. Groups of 3 animals received a single 10 mg/kg oral dose of compound formulated in water/0.5 % carboxymethylcellulose/0.4% Tween 80/0.5 % benzyl alcohol. Blood samples were collected over 48 h post-dosing by puncture of the lateral tail vein, and mixed 1:1 with de-ionized water 0.1% saponin and stored frozen at $-70^\circ C$ until analysis. After protein precipitation and liquid/liquid extraction, the samples were assayed by LC/MS using ESI conditions by selected ion monitoring in an API 4000 mass spectrometer (Applied Biosystems Sciex, Foster City, CA) coupled to a HPLC chromatograph (Agilent HP1100 Series, Agilent Technologies, Spain). Quantification was conducted by comparison to calibration curves prepared in blood. Blood concentration versus time data were analyzed by non-compartmental analysis (NCA) methods using WinNonlin® Professional Version 5.2.

Chemistry – Synthetic methods and experimental

General methods—Starting materials were obtained from commercial suppliers and used without further purification unless otherwise stated. Flash chromatography was carried out using pre-packed Isolute Flash or Biotage silica-gel columns as the stationary phase and analytical grade solvents as the eluent unless otherwise stated.

NMR spectra were determined on a Varian Unity spectrometer. Chemical shifts are reported as δ values (ppm) downfield from tetramethylsilane, used as an internal standard in the solvent indicated. All coupling constants are reported in hertz (Hz), and multiplicities are labelled br (broad), s (singlet), br s (broad singlet), d (doublet), t (triplet), q (quartet), dd

(doublet of doublets), dt (doublet of triplets), td (triplet of doublets), ddd (double-doubledoublet) and m (multiplet).

Total ion current traces were obtained for electrospray positive and negative ionisation (ES + / ES-) on a Waters ZMD 2000. Analytical chromatographic conditions used for the LC/MS analysis: Column: ACE, 4.6mm × 30mm. The stationary phase particle size is 3 µm and the flow rate was 1ml/min. Solvents were A: Aqueous solvent = Water + 0.1% Formic Acid; B: Organic solvent = Acetonitrile + 0.1% Formic Acid; Methods: 5 minute run time (0 – 0.2 min 10%B, 0.2 – 3.5 min 10 – 90% B, 3.5 – 4.01 min 90% B; 4.01 – 5 min 90 – 10% B. The following additional parameters were used: injection volume (5 µl), column temperature (30 °C), UV wavelength range (220–330 nm)

The purity of all tested compounds was ≥95% using the analytical method described above unless stated otherwise.

A table matching the synthetic intermediates to the final compounds is provided as Table S1, supplemental materials.

Synthesis of compounds 11–55, 100

These compounds were synthesized following the route described in Scheme 1 through intermediates **7**, **8a–b**, **9a–p** and **10a–p**.

2,3-diamino-6-methyl-4(3H)-pyrimidinone (7)—To a solution of EtONa prepared from sodium (9.19 g, 400 mmol) and Ethanol (350 mL), aminoguanidine hydrochloride (44.2 g, 400 mmol) was added and the reaction was heated at 50°C for 30 min. Then, the reaction was filtered to remove NaCl and ethyl 3-oxobutanoate (25.3 mL, 200 mmol) was added to the filtrate, the reaction mixture was heated at reflux for 5 h and, then, stirred at RT overnight. The precipitate obtained was filtered and dried under vacuum to afford intermediate **7**, a pale pink solid (15.2 g, 54% yield) ¹H NMR (400 MHz, DMSO-d₆) δ ppm: 7.02 (br s, 2H), 5.51 (br, 1H), 5.29 (s, 2H), 1.98 (s, 3H); ESIMS m/z 141 (MH)⁺.

General procedure for the synthesis of compounds **9a–9g** and **9j–9k**, **9m–9o**—

A solution of **7** (2.5 mmol) and the appropriate alkyl chloride (2.5 mmol) in a mixture of 1,4-dioxane (4 mL) and N,N-dimethylformamide (DMF) (1 mL) was heated at reflux overnight. In cases where the open, uncyclized intermediate was obtained, the reaction mixture was concentrated under vacuum, and the crude was dissolved in acetic acid (5 mL) and heated at reflux overnight. The reaction was then concentrated under vacuum and the residue was purified by flash chromatography on a silica gel column.

2-ethyl-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-ol (9a)—Eluting with DCM:MeOH mixtures from 100:0 to 90:10% to yield the title compound as a white solid (75% yield). ¹H NMR (400 MHz, CDCl₃) δ ppm: 5.89 (s, 1H), 2.87 (q, *J* = 7.4 Hz, 2H), 2.50 (s, 3H), 1.41 (t, *J* = 7.5 Hz, 3H); ESIMS m/z 179 (MH)⁺.

5-methyl-2-(1-methylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-ol (9b)—Eluting with DCM:MeOH mixtures, gradient from 100:0 to 90:10% to yield the title compound as a white solid (45% yield). ¹H NMR (300 MHz, DMSO-d₆) δ ppm: 13.21 - 12.82 (br, 1H), 5.76 (s, 1H), 3.06-2.96 (m, 1H), 2.28 (s, 3H), 1.28 (d, *J* = 6.9 Hz, 6H); ESIMS m/z 193 (MH)⁺.

5-methyl-2-(2-methylpropyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-ol (9c)—Eluting with DCM:MeOH mixtures, gradient from 100:0 to 90:10% to yield the title compound as a white solid (46% yield). ¹H NMR (300 MHz, DMSO-d₆) δ ppm: 13.01 (br s, 1H), 5.76 (s,

1H), 2.54 (d, J = 7.1 Hz, 2H), 2.49 (s, 3H), 2.09 - 2.04 (m, 1H), 0.92 (d, J = 6.6 Hz, 6H); ESIMS m/z 207 (MH)⁺.

2-(1,1-dimethylethyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-ol (9d)—Eluting with DCM:MeOH mixtures, gradient from 100:0 to 85:15% to yield the title compound as a white solid (71% yield). ¹H NMR (300 MHz, DMSO- d_6) δ ppm: 13.26 - 12.85 (br, 1H), 5.76 (s, 1H), 2.28 (s, 3H), 1.33 (s, 9H); ESIMS m/z 207 (MH)⁺.

5-methyl-2-(1-methylpropyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-ol (9e)—Eluting with DCM:MeOH mixtures, gradient from 99:1 to 85:15% to yield the title compound as a white solid (55% yield). ¹H NMR (300 MHz, DMSO- d_6) δ ppm: 13.33 - 12.78 (br, 1H), 5.76 (s, 1H), 2.85 - 2.76 (m, 1H), 2.28 (s, 3H), 1.79 - 1.68 (m, 1H), 1.65 - 1.55 (m, 1H), 1.25 (d, J = 6.8 Hz, 3H), 0.83 (t, J = 7.3 Hz, 3H); ESIMS m/z 207 (MH)⁺.

2-cyclopropyl-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-ol (9f)—Eluting with DCM:MeOH mixtures, gradient from 100:0 to 85:15% to yield the title compound as a white solid (22% yield). ¹H NMR (300 MHz, DMSO- d_6) δ ppm: 13.26 - 12.77 (br, 1H), 5.75 (s, 1H), 2.27 (s, 3H), 2.07 (m, 1H), 1.02 - 0.97 (m, 2H), 0.9 - 0.86 (m, 2H); ESIMS m/z 191 (MH)[−].

2-(cyclopropylmethyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-ol (9g)—Eluting with DCM:MeOH mixtures, gradient from 100:0 to 90:10% to yield the title compound as a pale yellow solid (24% yield). ¹H NMR (300 MHz, DMSO- d_6) δ ppm: 13.29 - 12.92 (br, 1H), 5.76 (s, 1H), 2.59 (d, J = 7.1 Hz, 2H), 2.29 (s, 3H), 1.14 - 1.03 (m, 1H), 0.50 - 0.46 (m, 2H), 0.24 - 0.21 (m, 2H); ESIMS m/z 205 (MH)⁺.

5-methyl-2-[(methyloxy)methyl][1,2,4]triazolo[1,5-a]pyrimidin-7-ol (9j)—Eluting with DCM:MeOH mixtures, gradient from 100:0 to 90:10% to yield the title compound as a white solid (87% yield). ¹H NMR (300 MHz, DMSO- d_6) δ ppm: 13.01 (br s, 1H), 5.81 (s, 1H), 4.45 (s, 2H), 3.32 (s, 3H), 2.30 (s, 3H); ESIMS m/z 195 (MH)⁺.

5-methyl-2-[2-(methyloxy)ethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-ol (9k)—Eluting with DCM:MeOH mixtures, gradient from 100:0 to 90:10% to yield the title compound as a white solid (58% yield). ¹H NMR (300 MHz, DMSO- d_6) δ ppm: 13.04 (br s, 1H), 5.77 (s, 1H), 3.70 (t, J = 6.6 Hz, 2H), 3.23 (s, 3H), 2.90 (t, J = 6.6 Hz, 2H), 2.28 (s, 3H); ESIMS m/z 209 (MH)⁺.

2-(2-chloroethyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-ol (9m)—Eluting with DCM:MeOH mixtures, gradient from 100:0 to 90:10% to yield the title compound as a white solid (31% yield). ¹H NMR (300 MHz, DMSO- d_6) δ ppm: 13.12 (br s, 1H), 5.79 (s, 1H), 3.98 (t, J = 6.6 Hz, 2H), 3.16 (t, J = 6.6 Hz, 2H), 2.29 (s, 3H); ESIMS m/z 213 (MH)⁺.

2-(chloromethyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-ol (9n)—Eluting with DCM:MeOH mixtures, gradient from 100:0 to 90:10% to yield the title compound as a white solid (58% yield). ¹H NMR (300 MHz, DMSO- d_6) δ ppm: 13.52 - 12.72 (br, 1H), 5.85 (s, 1H), 4.78 (s, 2H), 2.32 (s, 3H); ESIMS m/z 199 (MH)⁺.

5-methyl-2-[(phenylmethyl)oxy]methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-ol (9o)—Eluting with DCM:MeOH mixtures, gradient from 100:0 to 90:10% to yield the title compound as a white solid (72% yield). ¹H NMR (400 MHz, DMSO- d_6) δ ppm: 7.27 (m, 5H), 5.84 (s, 1H), 4.76 (s, 2H), 4.55 (s, 2H), 2.45 (s, 3H); ESIMS m/z 271 (MH)⁺.

General procedure for the synthesis of compounds 9h and 9i

To a solution of NaEtO prepared from sodium (143 mmol) and ethanol (150 mL), Intermediate **7** (71.4 mmol) was added and the reaction mixture was heated at 80 °C for 30 min. Then, the reaction mixture was cooled down to RT and ethyl 2,2-difluoropropanoate (1.2 equiv.) or ethyl 2,2-difluorobutanoate (1.2 equiv.) were added to synthesise **9h** or **9i** respectively. The mixture was stirred at RT for 30 min before being heated to 80 °C for 1.5 – 3 h. The reaction mixture was concentrated to dryness and water (200 mL) was added. The reaction mixture pH was adjusted to 4 by addition of 2N aq. HCl solution whilst a white solid precipitated. The solid was filtered off, washed with water and dried under vacuum to afford compounds **9h** or **9i**. The mother liquors were further extracted with DCM (5 × 35 mL) and the combined organic layers were dried over Na₂SO₄, filtered, and concentrated under vacuum to yield additional desired product.

2-(1,1-difluoroethyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-ol (9h)—White solid (73% yield). ¹H NMR (400 MHz, DMSO-d₆) δ ppm: 13.39 (br s, 1H), 5.91 (s, 1H), 2.33 (s, 3H), 2.06 (t, *J* = 19 Hz, 3H); ESIMS *m/z* 215 (MH)⁺.

2-(1,1-difluoropropyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-ol (9i)—White solid (53% yield). ¹H NMR (400 MHz, DMSO-d₆) δ ppm: 13.36 (br s, 1H), 5.90 (s, 1H), 2.40–2.32 (m, 2H), 2.32 (s, 3H), 0.99 (t, *J* = 7.6 Hz, 3H); ESIMS *m/z* 229 (MH)⁺.

General procedures for compounds 9l, 9p (Scheme 1)

2-(trifluoromethyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol (9l)—A mixture of ethyl 3-oxobutanoate (20 mmol) and 5-(trifluoromethyl)-4H-1,2,4-triazol-3-ylamine **8a** (20 mmol) (commercially available) was heated under reflux in acetic acid (10 mL) for 4–6 h and then concentrated. The product was then cooled to RT, filtered, washed with water, and dried under vacuum to give a pale pink solid with 50–65% yield. Mp: 172–174 °C, ¹H NMR (300 MHz, CDCl₃): δ ppm: 6.5 (br s, 1H), 6.0 (s, 1H), 2.40 (s, 3H). MS *m/z* 219.2 [M + H]⁺.

3-{2-[(phenylmethyl)oxy]ethyl}-1H-1,2,4-triazol-5-amine (8b)—To a solution of NaEtO prepared from sodium (0.237 g, 10.30 mmol) and Ethanol (10 mL), aminoguanidine hydrochloride (1.138 g, 10.30 mmol) was added and the reaction was heated at 50°C for 30 min. The reaction mixture was filtered to remove NaCl and methyl-3-benzyloxypropanoate (1 g, 5.15 mmol) was added. The reaction mixture was then heated at reflux for 5h, the formation of product being observed by TLC (90:10 DCM/MeOH) staining with KMnO₄. The reaction mixture was concentrated under vacuum and product was purified by flash chromatography (silica gel column, eluting with DCM/MeOH mixtures from 100:0 to 80:20%). Upon collection of the appropriate fractions, the title compound was obtained as a white solid (0.320 g, 29% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.36–7.28 (m, 5H), 4.57 (s, 2H), 3.79 (t, *J* = 6.6 Hz, 2H), 2.95 (t, *J* = 6.6 Hz, 2H); ESIMS *m/z* 219 (MH)⁺.

5-methyl-2-{2-[(phenylmethyl)oxy]ethyl}[1,2,4]triazolo[1,5-a]pyrimidin-7-ol (9p)—A solution of Intermediate **8b** (0.31 g, 1.42 mmol) and ethyl 3-oxobutanoate (0.216 mL, 1.704 mmol) in acetic acid (5 mL) was heated at 80°C overnight. The reaction mixture was concentrated under vacuum to obtain a pale yellow solid that was triturated in hexane to remove the excess of ethyl 3-oxobutanoate. After drying the solid under vacuum, the title compound was obtained as a pale yellow solid (0.39 g, 97% yield). ¹H NMR (300 MHz, DMSO-d₆) δ ppm: 13.05 (br s, 1H), 7.33–7.24 (m, 5H), 5.77 (s, 1H), 4.49 (s, 2H), 3.81 (t, *J* = 6.6 Hz, 2H), 2.96 (t, *J* = 6.6 Hz, 2H), 2.28 (s, 3H); ESIMS *m/z* 285 (MH)⁺.

General procedure for the synthesis of compounds 10a–10p—A suspension of Intermediate **9a–9p** (1.17 mmol) in phosphorous oxychloride (3.5 mmol) was heated at reflux for 1 h. The reaction mixture was added dropwise into iced water, neutralized with solid Na₂CO₃ and product was extracted with DCM. The combined organic layers were washed with brine and dried over anhydrous Na₂SO₄. A brown oil was obtained upon solvent removal in vacuo which was purified by flash chromatography on silica gel, eluting with Hexanes:EtOAc mixtures from 100:0 to 40:60%.

7-chloro-2-ethyl-5-methyl[1,2,4]triazolo[1,5-a]pyrimidine (10a)—White solid (76% yield). ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.01 (s, 1H), 2.98 (q, *J* = 7.6 Hz, 2H), 2.68 (s, 3H), 1.43 (t, *J* = 7.6 Hz, 3H); ESIMS *m/z* 197 (MH)⁺.

7-chloro-5-methyl-2-(1-methylethyl)[1,2,4]triazolo[1,5-a] pyrimidine (10b)—White solid (65% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.01 (s, 1H), 3.35–3.25 (m, 1H), 2.68 (s, 3H), 1.45 (d, *J* = 7.1 Hz, 6H); ESIMS *m/z* 211 (MH)⁺.

7-chloro-5-methyl-2-(2-methylpropyl)[1,2,4]triazolo[1,5-a]pyrimidine (10c)—White solid (85% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.01 (s, 1H), 2.82 (d, *J* = 7.1 Hz, 2H), 2.68 (s, 3H), 2.34–2.29 (m, 1H), 1.45 (d, *J* = 6.6 Hz, 6H); ESIMS *m/z* 225 (MH)⁺.

7-chloro-2-(1,1-dimethylethyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidine (10d)—Pale yellow solid (58% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 6.99 (s, 1H), 2.67 (s, 3H), 1.50 (s, 9H); ESIMS *m/z* 225 (MH)⁺.

7-chloro-5-methyl-2-(1-methylpropyl)[1,2,4]triazolo[1,5-a]pyrimidine (10e)—Colourless needles (56% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.01 (s, 1H), 3.12–3.03 (m, 1H), 2.68 (s, 3H), 2.02–1.91 (m, 1H), 1.81–1.7 (m, 1H), 1.42 (d, *J* = 7.1 Hz, 3H), 0.93 (t, *J* = 7.3 Hz, 3H); ESIMS *m/z* 225 (MH)⁺.

7-chloro-2-cyclopropyl-5-methyl[1,2,4]triazolo[1,5-a]pyrimidine (10f)—White solid (13% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 6.97 (s, 1H), 2.66 (s, 3H), 2.28–2.22 (m, 1H), 1.26–1.22 (m, 2H), 1.15–1.10 (m, 2H); ESIMS *m/z* 209 (MH)⁺.

7-chloro-2-(cyclopropylmethyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidine (10g)—Yellow solid (36% yield). ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm: 7.57 (s, 1H), 2.76 (d, *J* = 7.1 Hz, 2H), 2.660 (s, 3H), 1.24–1.12 (m, 1H), 0.52–0.48 (m, 2H), 0.28–0.24 (m, 2H); ESIMS *m/z* 223 (MH)⁺.

7-chloro-2-(1,1-difluoroethyl)-5-methyl[1,2,4]triazolo[1,5-a] pyrimidine (10h)—White solid (86% yield). ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.17 (s, 1H), 2.75 (s, 3H), 2.18 (t, *J* = 18.7 Hz, 3H); ESIMS *m/z* 233 (MH)⁺.

7-chloro-2-(1,1-difluoropropyl)-5-methyl[1,2,4]triazolo[1,5-a] pyrimidine (10i)—White solid (68% yield). ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.17 (s, 1H), 2.75 (s, 3H), 2.53–2.41 (m, 2H), 1.13 (t, *J* = 7.6 Hz, 3H); ESIMS *m/z* 247 (MH)⁺.

7-chloro-5-methyl-2-[(methyloxy)methyl][1,2,4]triazolo[1,5-a]pyrimidine (10j)—White solid (75% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.07 (s, 1H), 4.78 (s, 2H), 3.56 (s, 3H), 2.71 (s, 3H); ESIMS *m/z* 213 (MH)⁺.

7-chloro-5-methyl-2-[2-(methyloxy)ethyl][1,2,4]triazolo[1,5-a]pyrimidine (10k)—White solid (85% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.03 (s, 1H), 3.93 (t, *J* = 6.6 Hz, 2H), 3.38 (s, 3H), 3.24 (t, *J* = 6.6 Hz, 2H), 2.69 (s, 3H); ESIMS *m/z* 227 (MH)⁺.

7-chloro-5-methyl-2-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyrimidine (10l)—Mp: 102–105 °C, ¹H NMR (300 MHz, CDCl₃): δ ppm: 7.29 (s, 1H), 2.80 (s, 3H). MS *m/z* 237.0 [M + H]⁺.

7-chloro-2-(2-chloroethyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidine (10m)—White solid (67% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.06 (s, 1H), 4.04 (t, *J* = 6.6 Hz, 2H), 3.43 (t, *J* = 6.6 Hz, 2H), 2.70 (s, 3H); ESIMS *m/z* 231 (MH)⁺.

7-chloro-2-(chloromethyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidine (10n)—White solid (65% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.11 (s, 1H), 4.82 (s, 2H), 2.73 (s, 3H); ESIMS *m/z* 217 (MH)⁺.

7-chloro-5-methyl-2-[(phenylmethyl)oxy]methyl[1,2,4]triazolo[1,5-a]pyrimidine (10o)—White solid (87% yield). ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.44–7.35 (m, 5H), 7.07 (s, 1H), 4.84 (s, 2H), 4.77 (s, 2H), 2.71 (s, 3H); ESIMS *m/z* 289 (MH)⁺.

7-chloro-5-methyl-2-{2-[(phenylmethyl)oxy]ethyl}[1,2,4]triazolo[1,5-a]pyrimidine (10p)—White solid (0.31 g, 75% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.33–7.31 (m, 5H), 7.02 (s, 1H), 4.58 (s, 2H), 4.01 (t, *J* = 6.6 Hz, 2H), 3.28 (t, *J* = 6.6 Hz, 2H), 2.69 (s, 3H); ESIMS *m/z* 303 (MH)⁺.

General procedure for the synthesis of compounds 11–55, 100—To a suspension of Intermediate **10a–10p** (1 mmol) in Ethanol (5 mL), the corresponding aniline (1 mmol) was added and the mixture was stirred at RT or at 50 °C until the reaction reached completion. Ammonia in methanol (1 mmol) was added and solvent was removed *in vacuo* and the crude mixture was purified by flash chromatography (silica gel, eluting with Hexane:EtOAc mixtures from 75:25 to 25:75%) to yield the title compound.

N-(4-chlorophenyl)-2-ethyl-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (11)—Pale yellow solid (87% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.55 (d, *J* = 8.3 Hz, 2H), 7.45 (d, *J* = 8.3 Hz, 2H), 6.48 (s, 1H), 2.86 (q, *J* = 7.6 Hz, 2H), 2.43 (s, 3H), 1.34 (t, *J* = 7.6 Hz, 3H); ESIMS *m/z* 288 (MH)⁺.

N-(3-chlorophenyl)-2-ethyl-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (12)—Pale yellow solid (82% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.54–7.51 (m, 1H), 7.48–7.36 (m, 2H), 6.51 (s, 1H), 2.85 (q, *J* = 7.6 Hz, 2H), 2.44 (s, 3H), 1.34 (t, *J* = 7.6 Hz, 3H); ESIMS *m/z* 288 (MH)⁺.

2-ethyl-5-methyl-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (13)⁴²—White solid (90% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 10.37 (s, 1H), 7.80 (d, *J* = 8.5 Hz, 2H), 7.66 (d, *J* = 8.5 Hz, 2H), 6.60 (s, 1H), 2.84 (q, *J* = 7.6 Hz, 2H), 2.42 (s, 3H), 1.33 (t, *J* = 7.6 Hz, 3H); ESIMS *m/z* 322 (MH)⁺.

2-ethyl-5-methyl-N-[4-(pentafluoro-λ⁶-sulfanyl)phenyl][1,2,4]triazolo [1,5-a]pyrimidin-7-amine (14)⁴²—White solid (87% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 10.44 (br s, 1H), 7.95 (d, *J* = 8.3 Hz, 2H), 7.66 (d, *J* = 8.3 Hz, 2H), 6.68 (s, 1H), 2.83 (q, *J* = 7.3 Hz, 2H), 2.43 (s, 3H), 1.32 (t, *J* = 7.3 Hz, 3H); ESIMS *m/z* 380 (MH)⁺.

N-(4-chlorophenyl)-5-methyl-2-(1-methylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (15)—Colourless solid (35% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.77-7.63 (br, 1H), 7.49-7.45 (m, 2H), 7.36-7.31 (m, 2H), 6.27 (s, 1H), 3.29-3.19 (m, 1H), 2.58 (s, 3H), 1.46 (d, *J*= 7.1 Hz, 6H); ESIMS *m/z* 302 (MH)⁺.

N-(3-chlorophenyl)-5-methyl-2-(1-methylethyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (16)—White solid (14 % yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.79-7.68 (br, 1H), 7.45-7.39 (m, 2H), 7.33-7.27 (m, 2H), 6.36 (s, 1H), 3.30-3.19 (m, 1H), 2.56 (s, 3H), 1.45 (d, *J*=6.9 Hz, 6H); ESIMS *m/z* 302 (MH)⁺.

5-methyl-2-(1-methylethyl)-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (17)⁴²—White solid (29% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 8.00-7.86 (br, 1H), 7.77 (d, *J*= 8.3 Hz, 2H), 7.50 (d, *J*= 8.3 Hz, 2H), 6.47 (s, 1H), 3.32-3.22 (m, 1H), 2.58 (s, 3H), 1.46 (d, *J*= 6.9 Hz, 6H); ESIMS *m/z* 336 (MH)⁺.

5-methyl-2-(1-methylethyl)-N-[4-(pentafluoro-λ⁶-sulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (18)⁴²—White solid (35% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.96-7.83 (br, 3H), 7.47 (d, *J*= 8.8 Hz, 2H), 6.50 (s, 1H), 3.30-3.20 (m, 1H), 2.58 (s, 3H), 1.45 (d, *J*=6.9 Hz, 6H); ESIMS *m/z* 394 (MH)⁺.

N-(4-chlorophenyl)-5-methyl-2-(2-methylpropyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (19)—White solid (87% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 10.15 (s, 1H), 7.50 (d, *J*= 8.3 Hz, 2H), 7.46 (d, *J*= 8.3 Hz, 2H), 6.36 (s, 1H), 2.66 (d, *J*= 7.1 Hz, 2H), 2.38 (s, 3H), 2.26-2.22 (m, 1H), 0.96 (d, *J*= 6.6 Hz, 6H); ESIMS *m/z* 316 (MH)⁺.

N-(3-chlorophenyl)-5-methyl-2-(2-methylpropyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (20)—White solid (88% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 10.39 (s, 1H), 7.79 (d, *J*= 7.9 Hz, 2H), 7.67 (d, *J*= 7.3 Hz, 2H), 6.60 (s, 1H), 2.67 (d, *J*= 7.1 Hz, 2H), 2.42 (s, 3H), 2.21-2.17 (m, 1H), 0.96 (d, *J*= 6.6 Hz, 6H); ESIMS *m/z* 316 (MH)⁺.

5-methyl-2-(2-methylpropyl)-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (21)⁴²—White solid (96% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 10.19 (s, 1H), 7.55-7.41 (m, 3H), 7.33-7.31 (m, 1H), 6.41 (s, 1H), 2.67 (d, *J*= 7.1 Hz, 2H), 2.40 (s, 3H), 2.20-2.17 (m, 1H), 0.96 (d, *J*= 6.6 Hz, 6H); ESIMS *m/z* 350 (MH)⁺.

5-methyl-2-(2-methylpropyl)-N-[4-(pentafluoro-λ⁶-sulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (22)⁴²—White solid (92% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 10.45 (s, 1H), 7.95 (d, *J*= 8.7 Hz, 2H), 7.66 (d, *J*= 8.7 Hz, 2H), 6.67 (s, 1H), 2.68 (d, *J*= 7.1 Hz, 2H), 2.43 (s, 3H), 2.22-2.17 (m, 1H), 0.96 (d, *J*= 6.6 Hz, 6H); ESIMS *m/z* 408 (MH)⁺.

2-(1,1-dimethylethyl)-5-methyl-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (23)—White foam (66% yield). ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm: 10.15-10.04 (br, 1H), 7.81 (d, *J*= 8.6 Hz, 2H), 7.69-7.67 (m, 2H), 6.54 (s, 1H), 2.41 (s, 3H), 1.43 (s, 9H); ESIMS *m/z* 350 (MH)⁺.

2-(1,1-dimethylethyl)-5-methyl-N-[4-(pentafluoro-λ⁶-sulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (24)—White solid (49% yield). ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm: 10.2-10.08 (br, 1H), 7.96 (d, *J*= 9.1 Hz, 2H), 7.75-7.62 (m, 2H), 6.53 (s, 1H), 2.42 (s, 3H), 1.43 (s, 9H); ESIMS *m/z* 408 (MH)⁺.

5-methyl-2-(1-methylpropyl)-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (25)—White solid (35% yield). ¹H NMR (300 MHz, DMSO-d₆) δ ppm: 10.41-10.3 (br, 1H), 7.8 (d, *J* = 8.3 Hz, 2H), 7.69-7.67 (m, 2H), 6.59 (s, 1H), 2.98-2.89 (m, 1H), 2.42 (s, 3H), 1.9-1.79 (m, 1H), 1.73-1.62 (m, 1H), 1.33 (d, *J* = 7.07 Hz, 3H), 0.86 (t, *J* = 7.3 Hz, 3H); ESIMS *m/z* 350 (MH)⁺.

5-methyl-2-(1-methylpropyl)-N-[4-(pentafluoro-λ⁶-sulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (26)—White solid (39% yield). ¹H NMR (300 MHz, DMSO-d₆) δ ppm: 10.49-10.31 (br, 1H), 7.97-7.95 (m, 2H), 7.68-7.66 (m, 2H), 6.67 (s, 1H), 2.98-2.89 (m, 1H), 2.43 (s, 3H), 1.9-1.79 (m, 1H), 1.73-1.62 (m, 1H), 1.32 (d, *J* = 7.07 Hz, 3H), 0.88-0.84 (m, 3H); ESIMS *m/z* 408 (MH)⁺.

N-(4-chlorophenyl)-2-cyclopropyl-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (27)—White solid (69% yield). ¹H NMR (300 MHz, DMSO-d₆) δ ppm: 10.66-10.25 (br, 1H), 7.55-7.52 (m, 2H), 7.48-7.45 (m, 2H), 6.40 (s, 1H), 2.39 (s, 3H), 2.20-2.13 (m, 1H), 1.11-1.01 (m, 4H); ESIMS *m/z* 300 (MH)⁺.

N-(3-chlorophenyl)-2-cyclopropyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (28)—Beige solid (82% yield). ¹H NMR (300 MHz, DMSO-d₆) δ ppm: 10.53-10.26 (br, 1H), 7.52-7.48 (m, 2H), 7.45-7.42 (m, 1H), 7.38-7.35 (m, 1H), 6.45 (s, 1H), 2.41 (s, 3H), 2.20-2.13 (m, 1H), 1.10-1.01 (m, 4H); ESIMS *m/z* 300 (MH)⁺.

2-cyclopropyl-5-methyl-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (29)⁴²—White solid (26% yield). ¹H NMR (300 MHz, DMSO-d₆) δ ppm: 10.79-10.36 (br, 1H), 7.82 (d, *J* = 8.34 Hz, 2H), 7.67 (d, *J* = 8.34 Hz, 2H), 6.62 (s, 1H), 2.42 (s, 3H), 2.21-2.14 (m, 1H), 1.11-1.01 (m, 4H); ESIMS *m/z* 334 (MH)⁺.

2-cyclopropyl-5-methyl-N-[4-(pentafluoro-λ⁶-sulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (30)⁴²—Beige solid (60% yield). ¹H NMR (300 MHz, DMSO-d₆) δ ppm: 10.89-10.35 (br, 1H), 8.01-7.95 (m, 2H), 7.66 (d, *J* = 8.8 Hz, 2H), 6.69 (s, 1H), 2.43 (s, 3H), 2.20-2.14 (m, 1H), 1.10-1.01 (m, 4H); ESIMS *m/z* 392 (MH)⁺.

N-(4-chlorophenyl)-2-(cyclopropylmethyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (31)—White solid (60% yield). ¹H NMR (300 MHz, DMSO-d₆) δ ppm: 10.65-10.29 (br, 1H), 7.56-7.53 (m, 2H), 7.49-7.45 (m, 2H), 6.44 (s, 1H), 2.76 (d, *J* = 6.8 Hz, 2H), 2.42 (s, 3H), 1.24-1.14 (m, 1H), 0.54-0.50 (m, 2H), 0.31-0.27 (m, 2H); ESIMS *m/z* 314 (MH)⁺.

N-(3-chlorophenyl)-2-(cyclopropylmethyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (32)—White solid (75% yield). ¹H NMR (300 MHz, DMSO-d₆) δ ppm: 10.65-10.28 (br, 1H), 7.53-7.49 (m, 2H), 7.46-7.43 (m, 1H), 7.38-7.36 (m, 1H), 6.48 (s, 1H), 2.75 (d, *J* = 7.1 Hz, 2H), 2.43 (s, 3H), 1.24-1.15 (m, 1H), 0.54-0.49 (m, 2H), 0.31-0.27 (m, 2H); ESIMS *m/z* 314 (MH)⁺.

2-(cyclopropylmethyl)-5-methyl-N-(4-(trifluoromethyl)phenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (33)—White solid (11% yield). ¹H NMR (300 MHz, DMSO-d₆) δ ppm: 10.77-10.36 (br, 1H), 7.82 (d, *J* = 8.5 Hz, 2H), 7.68 (d, *J* = 8.5 Hz, 2H), 6.64 (s, 1H), 2.76 (d, *J* = 7.1 Hz, 2H), 2.44 (s, 3H), 1.25-1.14 (m, 1H), 0.54-0.49 (m, 2H), 0.30-0.27 (m, 2H); ESIMS *m/z* 348 (MH)⁺.

2-(cyclopropylmethyl)-5-methyl-N-(4-(pentafluoro-λ⁶-sulfanyl)phenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (34)—White solid (14% yield). ¹H NMR (300

MHz, DMSO- d_6) δ ppm: 10.67-10.38 (br, 1H), 7.99-7.95 (m, 2H), 7.67 (d, J = 8.8 Hz, 2H), 6.70 (s, 1H), 2.75 (d, J = 7.1 Hz, 2H), 2.45 (s, 3H), 1.25-1.14 (m, 1H), 0.53-0.49 (m, 2H), 0.30-0.26 (m, 2H); ESIMS m/z 406 (MH)⁺.

N-(4-chlorophenyl)-2-(1,1-difluoroethyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (35)—Beige solid (91% yield). ¹H NMR (400 MHz, DMSO- d_6) δ ppm: 10.35 (s, 1H), 7.53 (d, J = 8.3 Hz, 2H), 7.46 (d, J = 8.3 Hz, 2H), 6.45 (s, 1H), 2.42 (s, 3H), 2.12 (t, J = 18.7 Hz, 3H); ESIMS m/z 324 (MH)⁺.

N-(3-chlorophenyl)-2-(1,1-difluoroethyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (36)⁴²—Beige solid (91% yield). ¹H NMR (400 MHz, DMSO- d_6) δ ppm: 10.39 (s, 1H), 7.53-7.47 (m, 3H), 7.45-6.36 (m, 1H), 6.52 (s, 1H), 2.44 (s, 3H), 2.13 (t, J = 18.8 Hz, 3H); ESIMS m/z 324 (MH)⁺.

2-(1,1-difluoroethyl)-5-methyl-N-[4-(trifluoromethyl)phenyl][1,2,4] triazolo[1,5-a]pyrimidin-7-amine (37)⁴²—White solid (81% yield). ¹H NMR (300 MHz, DMSO- d_6) δ ppm: 10.58 (s, 1H), 7.83 (d, J = 8.5 Hz, 2H), 7.70 (d, J = 8.5 Hz, 2H), 6.73 (s, 1H), 2.47 (s, 3H), 2.14 (t, J = 18.8 Hz, 3H); ESIMS m/z 358 (MH)⁺.

2-(1,1-difluoroethyl)-5-methyl-N-[4-(pentafluoro- λ^6 -sulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (38)⁴²—White solid (81% yield). ¹H NMR (400 MHz, DMSO- d_6) δ ppm: 10.60 (br s, 1H), 7.97 (d, J = 9.3 Hz, 2H), 7.67 (d, J = 9.1 Hz, 2H), 6.79 (s, 1H), 2.47 (s, 3H), 2.13 (t, J = 18.9 Hz, 3H); ESIMS m/z 416 (MH)⁺.

N-(4-chlorophenyl)-2-(1,1-difluoropropyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (39)—White solid (88% yield). ¹H NMR (400 MHz, DMSO- d_6) δ ppm: 10.34 (s, 1H), 7.53 (d, J = 8.3 Hz, 2H), 7.48 (d, J = 8.3 Hz, 2H), 6.47 (s, 1H), 2.42-2.39 (m, 5H), 1.02 (t, J = 7.3 Hz, 3H); ESIMS m/z 338 (MH)⁺.

N-(3-chlorophenyl)-2-(1,1-difluoropropyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (40)—White solid (77% yield). ¹H NMR (400 MHz, DMSO- d_6) δ ppm: 10.38 (s, 1H), 7.54-7.48 (m, 3H), 7.38-7.36 (m, 1H), 6.52 (s, 1H), 2.44-2.39 (m, 5H), 1.02 (t, J = 7.3 Hz, 3H); ESIMS m/z 338 (MH)⁺.

2-(1,1-difluoropropyl)-5-methyl-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (41)⁴²—White solid (83% yield). ¹H NMR (400 MHz, DMSO- d_6) δ ppm: 10.58 (br s, 1H), 7.82 (d, J = 8.5 Hz, 2H), 7.67 (d, J = 8.4 Hz, 2H), 6.69 (s, 1H), 2.45 (s, 3H), 2.43-2.37 (m, 2H), 1.02 (t, J = 7.6 Hz, 3H); ESIMS m/z 372 (MH)⁺.

2-(1,1-difluoropropyl)-5-methyl-N-[4-(pentafluoro- λ^6 -sulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (42)⁴²—¹H NMR (400 MHz, DMSO- d_6) δ ppm: 10.63 (br s, 1H), 7.97 (d, J = 9.0 Hz, 2H), 7.67 (d, J = 8.7 Hz, 2H), 6.78 (s, 1H), 2.47 (s, 3H), 2.45-2.37 (m, 2H), 1.02 (t, J = 7.3 Hz, 3H); ESIMS m/z 430 (MH)⁺. Mp 132 – 134°C.

2-(trifluoromethyl)-N-(4-(trifluoromethyl)phenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (43)⁴²—Products were purified by column chromatography with 15–20% EtOAc/Hexane. Yields ranged from 20–30%. Mp: 124–126 °C; ¹H NMR (300 MHz, CDCl₃): δ 7.93 (brs, NH, exchangeable), 7.82 (d, J = 8.1 Hz, 2H), 7.54 (d, J = 8.7 Hz, 2H), 6.61 (s, 1H), 2.65 (s, 3H). MS m/z 362.3 [MH]⁺.

2-(trifluoromethyl)-N-(4-(sulfurpentafluoro)phenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (44)⁴²—Products were purified by column chromatography with

15–20% EtOAc/Hexane. Yields ranged from 20–30%. Mp: 178–180 °C. ¹H NMR (300 MHz, CDCl₃): δ 10.79 (brs, NH, exchangeable), 8.01 (d, *J* = 8.9 Hz, 2H), 7.70 (d, *J* = 9.2 Hz, 2H), 6.90 (s, 1H), 2.51 (s, 3H). MS *m/z* 420.3 [MH]⁺.

2-(chloromethyl)-N-(4-chlorophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (45a)—Brown foam (82% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.97–7.63 (br, 1H), 7.51–7.46 (m, 2H), 7.35–7.30 (m, 2H), 6.33 (s, 1H), 4.80 (s, 2H), 2.56 (s, 3H); ESIMS *m/z* 308 (MH)⁺.

2-(chloromethyl)-N-(3-chlorophenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (45b)—Orange oil (91% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.96–7.67 (br, 1H), 7.48–7.39 (m, 2H), 7.36–7.27 (m, 2H), 6.41 (s, 1H), 4.80 (s, 2H), 2.59 (s, 3H). *m/z* 308 (MH)⁺.

2-(2-chloroethyl)-N-(4-chlorophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (46a)—White solid (81% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.69 (s, 1H), 7.46 (d, *J* = 8.3 Hz, 2H), 7.29 (d, *J* = 8.3 Hz, 2H), 6.29 (s, 1H), 4.04 (t, *J* = 6.6 Hz, 2H), 3.37 (t, *J* = 6.6 Hz, 2H), 2.53 (s, 3H); ESIMS *m/z* 322 (MH)⁺.

2-(2-chloroethyl)-N-(3-chlorophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (46b)—White solid (96% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.76 (s, 1H), 7.43–7.28 (m 4 H), 6.38 (s, 1H), 4.04 (t, *J* = 6.6 Hz, 2H), 3.38 (t, *J* = 6.6 Hz, 2H), 2.56 (s, 3H); ESIMS *m/z* 322 (MH)⁺.

N-(4-chlorophenyl)-5-methyl-2-[(phenylmethyl)oxy]methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (47a)—Pale yellow solid (96% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.56 (d, *J* = 8.3 Hz, 2H), 7.47 (d, *J* = 8.3 Hz, 2H), 7.36–7.20 (m, 5H), 6.50 (s, 1H), 4.75 (s, 2H), 4.65 (s, 2H), 2.45 (s, 3H); ESIMS *m/z* 380 (MH)⁺.

N-(3-chlorophenyl)-5-methyl-2-[(phenylmethyl)oxy]methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (47b)—Pale yellow solid (97% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 7.52–7.30 (m, 9H), 6.54 (s, 1H), 4.75 (s, 2H), 4.65 (s, 2H), 2.46 (s, 3H); ESIMS *m/z* 380 (MH)⁺.

N-(4-chlorophenyl)-5-methyl-2-[(methyloxy)methyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (48)—White solid (70% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 10.28 (s, 1H), 7.52 (d, *J* = 8.3 Hz, 2H), 7.46 (d, *J* = 8.3 Hz, 2H), 6.41 (s, 1H), 4.59 (s, 2H), 3.37 (s, 3H), 2.40 (s, 3H); ESIMS *m/z* 304 (MH)⁺.

N-(3-chlorophenyl)-5-methyl-2-[(methyloxy)methyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (49)—White solid (79% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 10.32 (s, 1H), 7.51–7.45 (m, 3H), 7.35–7.32 (m, 1H), 6.46 (s, 1H), 4.60 (s, 2H), 3.37 (s, 3H), 2.42 (s, 3H); ESIMS *m/z* 304 (MH)⁺.

5-methyl-2-[(methyloxy)methyl]-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (50)—Pale yellow solid (90% yield). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm: 10.52 (s, 1H), 7.81 (d, *J* = 8.5 Hz, 2H), 7.68 (d, *J* = 8.5 Hz, 2H), 6.66 (s, 1H), 4.61 (s, 1H), 3.38 (s, 3H), 2.44 (s, 3H); ESIMS *m/z* 338 (MH)⁺.

5-methyl-2-[(methyloxy)methyl]-N-[4-(pentafluoro-λ⁶-sulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (51)—White solid (92% yield). ¹H NMR (400

MHz, DMSO- d_6) δ ppm: 10.59 (s, 1H), 7.98 (d, J = 8.7 Hz, 2H), 7.69 (d, J = 8.7 Hz, 2H), 6.75 (s, 1H), 4.63 (s, 2H), 3.39 (s, 3H), 2.47 (s, 3H); ESIMS m/z 396 (MH)⁺.

N-(4-chlorophenyl)-5-methyl-2-[2-(methyloxy)ethyl][1,2,4]triazolo[1,5-a]pyrimidine-7-amine (52)—White solid (93% yield). ¹H NMR (400 MHz, DMSO- d_6) δ ppm: 10.17 (s, 1H), 7.51 (d, J = 7.3 Hz, 2H), 7.45 (d, J = 7.3 Hz, 2H), 6.37 (s, 1H), 3.78 (t, J = 6.6 Hz, 2H), 3.25 (s, 3H), 3.03 (t, J = 6.6 Hz, 2H), 2.38 (s, 3H); ESIMS m/z 318 (MH)⁺.

N-(3-chlorophenyl)-5-methyl-2-[2-(methyloxy)ethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (53)—White solid (55% yield). ¹H NMR (400 MHz, DMSO- d_6) δ ppm: 10.19 (s, 1H), 7.51-7.46 (m, 2H), 7.37-7.34 (m, 1H), 6.42 (s, 1H), 3.79 (t, J = 6.6 Hz, 2H), 3.25 (s, 3H), 3.03 (t, J = 6.6 Hz, 2H), 2.40 (s, 3H); ESIMS m/z 318 (MH)⁺.

5-methyl-2-[2-(methyloxy)ethyl]-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (54)—White solid (86% yield). ¹H NMR (400 MHz, DMSO- d_6) δ ppm: 10.42 (s, 1H), 7.80 (d, J = 8.5 Hz, 2H), 7.66 (d, J = 8.5 Hz, 2H), 6.61 (s, 1H), 3.79 (t, J = 6.6 Hz, 2H), 3.25 (s, 3H), 3.04 (t, J = 6.6 Hz, 2H), 2.42 (s, 3H); ESIMS m/z 352 (MH)⁺.

5-methyl-2-[2-(methyloxy)ethyl]-N-[4-(pentafluoro- λ^6 -sulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (55)—White solid (72% yield). ¹H NMR (400 MHz, DMSO- d_6) δ ppm: 10.48 (s, 1H), 7.96 (d, J = 8.7 Hz, 2H), 7.66 (d, J = 8.7 Hz, 2H), 6.69 (s, 1H), 3.79 (t, J = 6.6 Hz, 2H), 3.25 (s, 3H), 3.04 (t, J = 6.6 Hz, 2H), 2.43 (s, 3H); ESIMS m/z 410 (MH)⁺.

Synthesis of compounds 66–84

These compounds were synthesized following the route described in Scheme 2 through intermediates **56–65**.

7-chloro-5-methyl-2-(methylthio)[1,2,4]triazolo[1,5-a]pyrimidine (57)—A suspension of commercially available 7-hydroxy-5-methyl-2-methylthio-S-triazolo[1,5-a]pyrimidine (**56**) (2 g, 10.19 mmol) in phosphorus oxychloride (5 mL, 53.6 mmol) was heated at reflux for 10h, the starting material solubilizing and the mixture turning bright orange. TLC analysis (Hexane/EtOAc 1:1) showed a very messy reaction that had not reached completion, but it was decided to stop it to prevent further product degradation. Hence, the reaction mixture was added dropwise to iced water. The solution was neutralized with aq. 1N Na₂CO₃ and product was extracted with DCM. The aqueous layer was further extracted with DCM and the combined organic layers were washed with brine and dried over anhydrous Na₂SO₄. Solvent was removed under reduced pressure yielding a reddish solid which was purified by flash chromatography (silica gel, eluting with Hexane/EtOAc mixtures from 95:5 to 40:60%). Upon collection of the appropriate fractions, the title compound was obtained as a white solid (1.09 g, 47% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 6.99 (s, 1H), 2.74 (s, 3H), 2.68 (s, 3H); ESIMS m/z 215 (MH)⁺.

General Procedures for the synthesis of compounds 58–61

To a suspension of Intermediate **57** (1 mmol) in Ethanol (10 mL), the appropriate aniline (1 mmol) was added and the mixture was stirred at RT until reaching completion. Anhydrous ammonia (7M solution in MeOH, 1 mmol) was then added to the mixture and solvent was removed *in vacuo*. The crude mixture was purified by flash chromatography (silica gel, eluting with Hexane/EtOAc mixtures from 95:5 to 40:60%).

N-(4-chlorophenyl)-5-methyl-2-(methylthio)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (58)—Beige solid (86% yield). ¹H NMR (300 MHz, DMSO-d₆) δ ppm: 10.81-10.15 (br, 1H), 7.57-7.54 (m, 2H), 7.48-7.45 (m, 2H), 6.42 (s, 1H), 2.69 (s, 3H), 2.42 (s, 3H); ESIMS m/z 306 (MH)⁺.

N-(3-chlorophenyl)-5-methyl-2-(methylthio)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (59)—Pale yellow solid (61% yield). ¹H NMR (300 MHz, DMSO-d₆) δ ppm: 11.26-10.10 (br, 1H), 7.55-7.5 (m, 2H), 7.45-7.39 (m, 2H), 6.48 (s, 1H), 2.69 (s, 3H), 2.44 (s, 3H); ESIMS m/z 306 (MH)⁺.

5-methyl-2-(methylthio)-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (60)⁴²—White solid (86% yield). ¹H NMR (300 MHz, DMSO-d₆) δ ppm: 10.33 (s, 1H), 7.81 (d, *J* = 8.3 Hz, 2H), 7.67 (d, *J* = 8.3 Hz, 2H), 6.62 (s, 1H), 2.68 (s, 3H), 2.42 (s, 3H); ESIMS m/z 340 (MH)⁺.

5-methyl-2-(methylthio)-N-[4-(pentafluoro-λ⁶-sulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (61)⁴²—Light yellow solid (72% yield). ¹H NMR (300 MHz, DMSO-d₆) δ ppm: 10.39 (s, 1H), 7.98-7.96 (m, 2H), 7.66 (d, *J* = 8.8 Hz, 2H), 6.70 (s, 1H), 2.68 (s, 3H), 2.44 (s, 3H); ESIMS m/z 398 (MH)⁺.

General Procedures for the synthesis of compounds 62–65 (Scheme 2)—To a mixture of the corresponding derivative **58–61** (1 mmol) and acetic acid (7 mL), sodium tungstate dihydrate (0.034 mmol) was added at RT. The reaction mixture was vigorously stirred and hydrogen peroxide (2 mmol) was added slowly at 40 °C. The resulting mixture was then heated at 50 °C until reaching completion. The excess hydrogen peroxide was destroyed by the addition of an aqueous solution of sodium sulfite, product being extracted with DCM several times. The combined organic layers were washed with brine and dried over anhydrous Na₂SO₄. A white solid was obtained upon solvent removal in vacuo which was purified by flash chromatography (silica gel, eluting with Hexane/EtOAc mixtures from 95:5% to 0:100%).

N-(4-chlorophenyl)-5-methyl-2-(methylsulfonyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (62)—White solid (36% yield). ¹H NMR (300 MHz, DMSO-d₆) δ ppm: 10.58 (s, 1H), 7.57-7.54 (m, 2H), 7.50-7.47 (m, 2H), 6.57 (s, 1H), 3.48 (s, 3H), 2.46 (s, 3H); ESIMS m/z 338 (MH)⁺.

N-(3-chlorophenyl)-5-methyl-2-(methylsulfonyl)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (63)—White solid (35% yield). ¹H NMR (300 MHz, DMSO-d₆) δ ppm: 10.62 (br s, 1H), 7.55-7.37 (m, 4H), 6.62 (s, 1H), 3.48 (s, 3H), 2.48 (s, 3H); ESIMS m/z 338 (MH)⁺.

5-methyl-2-(methylsulfonyl)-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (64)—White solid (56% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 8.18 (br s, 1H), 7.81-7.79 (m, 2H), 7.53 (d, *J* = 8.3 Hz, 2H), 6.63 (s, 1H), 3.44 (s, 3H), 2.64 (s, 3H); ESIMS m/z 372 (MH)⁺.

5-methyl-2-(methylsulfonyl)-N-[4-(pentafluoro-λ⁶-sulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (65)—White solid (51% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 8.23-8.10 (br s, 1H), 7.93-7.91 (m, 2H), 7.50 (d, *J* = 8.6 Hz, 2H), 6.67 (s, 1H), 3.44 (s, 3H), 2.66 (s, 3H); ESIMS m/z 430 (MH)⁺.

General Procedures for the synthesis of compounds 66–86 (Scheme 2)—The appropriate derivative **62–65** (0.15 g, 0.349 mmol) was added to sodium methoxide (3 mmol) in Methanol (9 mL) (**66**, **67**), or sodium ethoxide (3 mmol) in Ethanol (9 mL) (**68–71**) or to the appropriate alcohol (1.2 mmol) with sodium hydride (2 mmol) in THF (7 mL) (**72–84**). The mixture was heated under microwave irradiation at 120 °C for 0.5 – 1 h. Solvent was removed under vacuum and the crude mixture was purified by flash chromatography (silica gel, eluting with DCM: MeOH mixtures from 100:0 to 90:10%) or preparative HPLC (SunFire 30× 250 mm, H₂O 0.1% TFA-ACN 0.1% TFA gradient from 20 to 80%).

N-(3-chlorophenyl)-5-methyl-2-(methyloxy)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (66)—White solid (33% yield). ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm: 10.44-9.95 (br, 1H), 7.52-7.41 (m, 3H), 7.37-7.34 (m, 1H), 6.43 (s, 1H), 4.06 (s, 3H), 2.39 (s, 3H); ESIMS *m/z* 290 (MH)⁺.

N-(4-chlorophenyl)-5-methyl-2-(methyloxy)[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (67)—White solid (57% yield). ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm: 10.25-9.96 (br, 1H), 7.55-7.49 (m, 2H), 7.49-7.42 (m, 2H), 6.38 (s, 1H), 4.05 (s, 3H), 2.37 (s, 3H); ESIMS *m/z* 290 (MH)⁺.

N-(3-chlorophenyl)-2-(ethyloxy)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (68)—White solid (74% yield). ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm: 10.42-9.97 (br, 1H), 7.52-7.40 (m, 3H), 7.37-7.34 (m, 1H), 6.43 (s, 1H), 4.46 (q, *J* = 7.1 Hz, 2H), 2.39 (s, 3H), 1.39 (t, *J* = 7.1 Hz, 3H); ESIMS *m/z* 304 (MH)⁺.

N-(4-chlorophenyl)-2-(ethyloxy)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (69)—White solid (74% yield). ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm: 10.24-9.99 (br, 1H), 7.54-7.52 (m, 2H), 7.47-7.43 (m, 2H), 6.38 (s, 1H), 4.46 (q, *J* = 7.0 Hz, 2H), 2.37 (s, 3H), 1.39 (t, *J* = 7.0 Hz, 3H); ESIMS *m/z* 304 (MH)⁺.

2-(ethyloxy)-5-methyl-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (70)⁴²—Beige solid (66% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.79-7.71 (br, 3H), 7.46 (d, *J* = 8.3 Hz, 2H), 6.47 (s, 1H), 4.56 (q, *J* = 7.1 Hz, 2H), 2.55 (s, 3H), 1.49 (t, *J* = 7.1 Hz, 3H); ESIMS *m/z* 338 (MH)⁺.

2-(ethyloxy)-5-methyl-N-[4-(pentafluoro-λ⁶-sulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (71)⁴²—White solid (41% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.91-7.85 (m, 2H), 7.82-7.76 (br, 1H), 7.43 (d, *J* = 8.8 Hz, 2H), 6.51 (s, 1H), 4.56 (q, *J* = 7.1 Hz, 2H), 2.56 (s, 3H), 1.49 (t, *J* = 7.1 Hz, 3H); ESIMS *m/z* 396 (MH)⁺.

N-(4-chlorophenyl)-5-methyl-2-[[2-(methyloxy)ethyl]oxy][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (72)—White solid (46% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.51-7.49 (m, 2H), 7.33-7.31 (m, 2H), 6.26 (s, 1H), 4.63 (t, *J* = 4.6 Hz, 2H), 3.71 (d, *J* = 84.6 Hz, 2H), 3.45 (s, 3H), 2.5 (s, 3H); ESIMS *m/z* 334 (MH)⁺.

N-(3-chlorophenyl)-5-methyl-2-[[2-(methyloxy)ethyl]oxy][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (73)—White solid (58% yield). ¹H NMR (300 MHz, DMSO-*d*₆) δ ppm: 10.26-9.98 (br, 1H), 7.51-7.47 (m, 2H), 7.43-7.40 (m, 1H), 7.36-7.33 (m, 1H), 6.43 (s, 1H), 4.53-4.51 (m, 2H), 3.71-3.69 (m, 2H), 3.3 (s, 3H), 2.38 (s, 3H); ESIMS *m/z* 334 (MH)⁺.

N-(4-chlorophenyl)-5-methyl-2-[[2-(methylamino)ethyl]oxy][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (74)—White solid (61% yield). ¹H NMR (300 MHz, DMSO-d₆) δ ppm: 10.05-9.84 (br, 1H), 8.82-8.59 (br, 1H), 7.57-7.5 (m, 2H), 7.47-7.43 (m, 2H), 6.39 (s, 1H), 4.67-4.63 (m, 2H), 3.49-3.37 (br, 2H), 2.68-2.64 (m, 3H), 2.38 (s, 3H); ESIMS m/z 333 (MH)⁺.

N-(3-chlorophenyl)-5-methyl-2-[[2-(methylamino)ethyl]oxy][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (75)—White solid (38% yield). ¹H NMR (300 MHz, DMSO-d₆) δ ppm: 10.09-9.90 (br, 1H), 8.84-8.6 (br, 1H), 7.53-7.48 (m, 2H), 7.44-7.35 (m, 2H), 6.45 (s, 1H), 4.65 (t, *J* = 4.8 Hz, 2H), 3.56-3.33 (br, 2H), 2.68-2.64 (m, 3H), 2.40 (s, 3H); ¹H NMR (300 MHz, CDCl₃) δ ppm: 10.36-9.91 (br, 2H), 7.44-7.27 (m, 4H), 6.18 (s, 1H), 4.99-4.78 (br, 2H), 3.7-3.49 (br, 2H), 2.91 (s, 3H), 2.32 (s, 3H); ESIMS m/z 333 (MH)⁺.

5-methyl-2-[[2-(methylamino)ethyl]oxy]-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (76)—White solid (48% yield). ¹H NMR (300 MHz, DMSO-d₆) δ ppm: 10.25-10.15 (br, 1H), 8.82-8.6 (br, 1H), 7.84-7.81 (m, 2H), 7.65 (d, *J* = 8.5 Hz, 2H), 6.64 (s, 1H), 4.68-4.64 (m, 2H), 3.64-3.26 (br, 2H), 2.68-2.64 (m, 3H), 2.42 (s, 3H); ESIMS m/z 367 (MH)⁺.

5-methyl-2-[[2-(methylamino)ethyl]oxy]-N-[4-(pentafluoro-λ⁶-sulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (77)—White solid (25% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 9.92-9.67 (br, 2H), 7.88-7.86 (m, 2H), 7.55 (d, *J* = 8.6 Hz, 2H), 6.34 (s, 1H), 4.93-4.82 (m, 2H), 3.70-3.51 (br, 2H), 2.96-2.84 (br, 3H), 2.43 (s, 3H); ESIMS m/z 425 (MH)⁺.

N-(4-chlorophenyl)-2-[[2-(dimethylamino)ethyl]oxy]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (78)—White solid (20% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 13.26-11.23 (br, 1H), 7.52-7.46 (m, 2H), 7.36-7.34 (m, 2H), 6.26 (s, 1H), 4.9-4.88 (m, 2H), 3.66-3.64 (m, 2H), 3.00 (s, 6H), 2.51 (s, 3H); ESIMS m/z 347 (MH)⁺.

N-(3-chlorophenyl)-2-[[2-(dimethylamino)ethyl]oxy]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (79)—White solid (38% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.46-7.4 (m, 2H), 7.36-7.27 (m, 2H), 6.34 (s, 1H), 4.9-4.88 (m, 2H), 3.66-3.64 (m, 2H), 2.97 (s, 6H), 2.53 (s, 3H); ESIMS m/z 347 (MH)⁺.

2-[[2-(dimethylamino)ethyl]oxy]-5-methyl-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (80)—White solid (7% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.76 (d, *J* = 8.6 Hz, 2H), 7.53 (d, *J* = 8.6 Hz, 2H), 6.47 (s, 1H), 4.93-4.91 (m, 2H), 3.63 (t, *J* = 4.9 Hz, 2H), 2.99 (s, 6H), 2.55 (s, 3H); ESIMS m/z 381 (MH)⁺.

2-[[2-(dimethylamino)ethyl]oxy]-5-methyl-N-[4-(pentafluoro-λ⁶-sulfanyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (81)—White solid (13% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.88 (d, *J* = 8.8 Hz, 2H), 7.51 (d, *J* = 8.6 Hz, 2H), 6.51 (s, 1H), 4.92 (t, *J* = 5.1 Hz, 2H), 3.61 (t, *J* = 5.1 Hz, 2H), 2.97 (s, 6H), 2.56 (s, 3H); ESIMS m/z 439 (MH)⁺.

2-[(2-aminoethyl)oxy]-N-(3-chlorophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (82)—White solid (54% yield). ¹H NMR (300 MHz, DMSO-d₆) δ ppm: 10 (s, 1H), 8.05 (br, 2H), 7.53-7.49 (m, 2H), 7.44-7.42 (m, 1H), 7.38-7.36 (m, 1H), 6.44 (s, 1H), 4.59 (t, *J* = 4.9 Hz, 2H), 3.35-3.31 (m, 2H), 2.39 (s, 3H); ESIMS m/z 319 (MH)⁺.

2-[(2-aminoethyl)oxy]-5-methyl-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (83)—White solid (46% yield). ¹H NMR (300 MHz, DMSO-d₆) δ ppm: 10.35-10.08 (br, 1H), 8.06 (br, 2H), 7.83 (d, *J* = 8.6 Hz, 2H), 7.67-7.65 (m, 2H), 6.63 (s, 1H), 4.61-4.56 (m, 2H), 3.35-3.31 (m, 2H), 2.41 (s, 3H); ESIMS *m/z* 353 (MH)⁺.

2-[(2-aminoethyl)oxy]-N-(4-chlorophenyl)-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (84)—White solid (18% yield). ¹H NMR (300 MHz, DMSO-d₆) δ ppm: 9.97 (s, 1H), 8.04 (br, 2H), 7.54 (d, *J* = 8.6 Hz, 2H), 7.45 (d, *J* = 8.6 Hz, 2H), 6.39 (s, 1H), 4.59 (t, *J* = 4.9 Hz, 2H), 3.34-3.31 (m, 2H), 2.37 (s, 3H); ESIMS *m/z* 319 (MH)⁺.

General Procedures for the synthesis of compounds 85–86—These compounds were obtained as a by-product in the reaction yielding **78–79**, probably due to the presence of NaOH in the reaction medium.

7-[(4-chlorophenyl)amino]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2(1H)-one (85)—White solid (21% yield). ¹H NMR (300 MHz, DMSO-d₆) δ ppm: 10.09 (br s, 1H), 7.51 (d, *J* = 8.8 Hz, 2H), 7.42 (d, *J* = 8.8 Hz, 2H), 6.44 (br s, 1H), 5.75 (s, 1H), 2.32 (s, 3H); ¹H NMR (300 MHz, DMSO-d₆+D₂O) δ ppm: 7.51-7.49 (m, 2H), 7.42 (d, *J* = 8.8 Hz, 2H), 6.45 (s, 1H), 5.73 (s, 1H), 2.32 (s, 3H); ESIMS *m/z* 276 (MH)⁺.

7-[(3-chlorophenyl)amino]-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2(1H)-one (86)—White solid (38% yield). ¹H NMR (300 MHz, DMSO-d₆) δ ppm: 10.16 (br s, 1H), 7.50-7.46 (m, 2H), 7.41-7.39 (m, 1H), 7.35-7.33 (m, 1H), 6.49 (s, 1H), 5.76 (s, 1H), 2.34 (s, 3H); ¹H NMR (300 MHz, DMSO-d₆+D₂O) δ ppm: 7.50-7.46 (m, 2H), 7.39-7.33 (m, 2H), 6.48 (s, 1H), 5.69 (s, 1H), 2.33 (s, 3H); ESIMS *m/z* 276 (MH)⁺.

General Procedures for the synthesis of 89–97 (Scheme 3)

The corresponding amine (10 equiv.) in MeOH or THF was added to a solution of the corresponding 2-(chloromethyl) triazolopyrimidine derivative (Intermediates **45a,b** or **46a,b**) (1 mmol) in Tetrahydrofuran (THF) (6 mL). The mixture was heated under microwave irradiation at 120 °C for 30–45 minutes. Whenever reaction completion had not been reached, more amine in MeOH or THF (10 mmol) was added. The mixture was microwave irradiated at 120 °C until reaction completion had been reached. The mixture was then filtered and solvent was removed under reduced pressure. The crude mixture was purified by preparative HPLC (SunFire 19× 150 mm, H₂O 0.1% TFA-ACN 0.1% TFA gradient from 10 to 100%). Upon freeze-drying of the corresponding fractions, desired product was obtained.

N-(4-chlorophenyl)-5-methyl-2-[2-(methylamino)ethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (89)—White solid (68% yield). ¹H NMR (400 MHz, DMSO-d₆) δ ppm: 9.57 (br s, 1H), 7.53 (d, *J* = 7.3 Hz, 2H), 7.47 (d, *J* = 7.3 Hz, 2H), 6.42 (s, 1H), 3.33 (s, 3H), 3.32-3.27 (m, 2H), 2.61-2.33 (m, 4H); ESIMS *m/z* 317 (MH)⁺.

2-(aminomethyl)-N-(4-chlorophenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (90)—White solid (16% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 9.52-8.38 (br, 2H), 7.35 (d, *J* = 8.6 Hz, 2H), 7.30-7.27 (m, 2H), 6.20 (s, 1H), 4.53 (br s, 2H), 2.46 (s, 3H); ESIMS *m/z* 289 (MH)⁺.

N-(4-chlorophenyl)-5-methyl-2-((methylamino)methyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (91)—White solid (71% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 10.61-9.65 (br, 1H), 7.53-7.44 (m, 4H), 6.24 (s, 1H), 4.40 (s, 2H), 2.97 (s, 3H), 2.49 (s, 3H); ESIMS *m/z* 303 (MH)⁺.

N-(4-chlorophenyl)-2-((dimethylamino)methyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (92)—White solid (31% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.50-7.47 (m, 2H), 7.41-7.37 (m, 2H), 6.42 (s, 1H), 4.53 (s, 2H), 3.05 (s, 6H), 2.58 (s, 3H); ESIMS m/z 317 (MH)⁺.

N-(3-chlorophenyl)-5-methyl-2-[2-(methylamino)ethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (93)—White solid (53% yield). ¹H NMR (400 MHz, DMSO-d₆) δ ppm: 9.57 (br s, 1H), 7.53-7.33 (m, 4H), 7.47 (d, *J* = 7.3 Hz, 2H), 6.48 (s, 1H), 3.33 (s, 3H), 3.23-3.20 (m, 2H), 2.64-2.34 (m, 4H); ESIMS m/z 317 (MH)⁺.

N-(3-chlorophenyl)-2-((dimethylamino)methyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (94)—Pale yellow solid (56% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 7.46-7.42 (m, 2H), 7.35-7.32 (m, 2H), 6.48 (s, 1H), 4.49 (s, 2H), 3.03 (s, 6H), 2.59 (s, 3H); ESIMS m/z 317 (MH)⁺.

2-(aminomethyl)-N-(3-chlorophenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (95)—Pale yellow solid (11% yield). ¹H NMR (300 MHz, MeOH-d₄) δ ppm: 7.53-7.50 (m, 2H), 7.43-7.40 (m, 2H), 6.50 (s, 1H), 4.42 (s, 2H), 2.52 (s, 3H); ESIMS m/z 289 (MH)⁺.

N-(3-chlorophenyl)-5-methyl-2-((methylamino)methyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (96)—White solid (21% yield). ¹H NMR (300 MHz, CDCl₃) δ ppm: 10.7-10.08 (br, 1H), 7.39-7.32 (m, 2H), 7.28-7.27 (m, 2H), 6.31 (s, 1H), 4.39 (s, 2H), 2.97 (s, 3H), 2.50 (s, 3H); ESIMS m/z 303 (MH)⁺.

2-(2-aminoethyl)-N-(4-chlorophenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (97)—White solid (40% yield). ¹H NMR (400 MHz, DMSO-d₆) δ ppm: 7.77 (br s, 2H), 7.53 (d, *J* = 7.3 Hz, 2H), 7.47 (d, *J* = 7.3 Hz, 2H), 6.42 (s, 1H), 3.27 (m, 2H), 3.25 (m, 2H), 2.40 (s, 3H); ESIMS m/z 303 (MH)⁺.

General procedures for the synthesis of 98 and 99 (Scheme 4)

10% Palladium on activated charcoal (330.06 mmol) was placed in a hydrogenation flask under N₂ atmosphere; intermediate **47a** or **47b** (1 mmol) dissolved in Acetic Acid (10 mL) was added. The reaction mixture was hydrogenated at 35 psi and checked at 16 h, 30 h and 40 h. After this time, LCMS showed a mixture of starting material, de-halogenated starting material, desired product and dehalogenated desired product in ratio (35/5/50/10). The reaction mixture was concentrated under vacuum and purified by preparative HPLC (SunFire, H₂O 0.1% TFA-ACN 0.1% TFA gradient from 10 to 100%). After collection of the appropriate fractions, solvent was evaporated under reduced pressure and the product was dried under vacuum in presence of phosphorous pentoxide overnight to give the desired product.

{7-[(4-chlorophenyl)amino]-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}methanol (98)—White solid (11% yield). ¹H NMR (400 MHz, DMSO-d₆) δ ppm: 10.52 (br s, 1H), 7.53 (d, *J* = 8.3 Hz, 2H), 7.46 (d, *J* = 8.3 Hz, 2H), 6.45 (s, 1H), 4.66 (s, 2H), 2.42 (s, 3H); ESIMS m/z 290 (MH)⁺.

{7-[(3-chlorophenyl)amino]-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}methanol (99)—White solid (12% yield). ¹H NMR (400 MHz, DMSO-d₆) δ ppm: 10.36 (br s, 1H), 7.52-7.45 (m, 3H), 7.37-7.34 (m, 1H), 6.50 (s, 1H), 4.66 (s, 2H), 2.42 (s, 3H); ESIMS m/z 290 (MH)⁺.

Synthesis of compound 101 (Scheme 4)

5-methyl-2-{2-[(phenylmethyl)oxy]ethyl}-N-[4-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine (100)—A suspension of Intermediate **10p** (0.302 g, 0.997 mmol) and 4-(trifluoromethyl)aniline (0.125 mL, 0.997 mmol) in Ethanol (5 mL) was heated at 50°C for 1h. The reaction mixture was concentrated under vacuum, taken up with DCM (20 mL) and washed with Na₂CO₃ (2 × 15 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under vacuum to afford a pale yellow solid (0.407 g, 95% yield). ¹H NMR (300 MHz, DMSO-d₆) δ ppm: 10.02 (s, 1H), 7.79 (d, *J* = 8.6 Hz, 2H), 7.67 (d, *J* = 8.6 Hz, 2H), 7.32–7.25 (m, 5H), 6.61 (s, 1H), 4.51 (s, 2H), 3.90 (t, *J* = 6.6 Hz, 2H), 3.10 (t, *J* = 6.6 Hz, 2H), 2.42 (s, 3H); ESIMS *m/z* 428 (MH)⁺.

2-(5-methyl-7-{[4-(trifluoromethyl)phenyl]amino}[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)ethanol (101)—A solution of Intermediate **100** (0.25 g, 0.585 mmol) in methanol (3 mL) was hydrogenated using 10% Pd/C as catalyst. The reaction mixture was concentrated and the residue was purified by flash chromatography (silica gel column, eluting with DCM:MeOH mixtures from 100:0 to 90:10%). Upon collection of the appropriate fractions, the title compound was obtained as a white solid (0.055 g, 30% yield). ¹H NMR (400 MHz, DMSO-d₆) δ ppm: 10.40 (s, 1H), 7.80 (d, *J* = 8.6 Hz, 2H), 7.67 (d, *J* = 8.6 Hz, 2H), 6.60 (s, 1H), 4.72 (t, *J* = 5.5 Hz, 1H), 3.85 (q, *J* = 6.8 Hz, 2H), 2.96 (t, *J* = 6.8 Hz, 2H), 2.43 (s, 3H); ESIMS *m/z* 338 (MH)⁺.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The team acknowledges Dr. Dennis Kyle for providing the atovaquone resistant lines TM90C2B and TM90C2A, Dr. Akhil Vaidya for providing the D10 cell line harboring yeast DHODH, and Dr. Leonard D. Shultz and The Jackson Laboratory for providing access to NOD-*scid* IL-2Rγ^{null} for the *in vivo* evaluation of compounds in the *P. falciparum* murine model through collaboration with GlaxoSmithKline. The team also acknowledges Emma Castro and Angel Pajares (Red Cross Blood Bank, Madrid, Spain) for the supply of human erythrocytes to perform the *in vivo* experiments in the *P. falciparum* murine model.

This work was supported by the United States National Institutes of Health grants, U01AI075594 (to MAP, PKR, SAC and IB) and R01AI53680 (to MAP and PKR). MAP acknowledges support of the Welch Foundation (I-1257) and PKR also acknowledges a Grand Challenge Explorations Award from the Bill and Melinda Gates Foundation. MAP holds the Carolyn R. Bacon Professorship in Medical Science and Education.

Abbreviations

<i>Pf</i>DHODH	<i>P. falciparum</i> dihydroorotate dehydrogenase
<i>Pb</i>DHODH	<i>P. berghei</i> DHODH
<i>Pv</i>DHODH	<i>P. vivax</i> DHODH
<i>h</i>DHODH	human DHODH
CoQ	ubiquinone
FMN	flavin mononucleotide
HTS	high throughput screen
ACTs	artemisinin-based combination therapies
ADME	adsorption, distribution, metabolism, excretion

SAR structure activity relationships

References

1. Meshnick, SR.; Dobson, MJ. The history of antimalarial drugs. In: Rosenthal, P., editor. Antimalarial chemotherapy: mechanisms of action, resistance, and new directions in drug discovery. Humana Press Inc; Totowa, NJ: 2001. p. 15-25.
2. Guerra CA, Gikandi PW, Tatem AJ, Noor AM, Smith DL, Hay SI, Snow RW. The limits and intensity of *Plasmodium falciparum* transmission: implications for malaria control and elimination worldwide. *PLoS Med.* 2008; 5:e38. [PubMed: 18303939]
3. Greenwood BM, Fidock DA, Kyle DE, Kappe SH, Alonso PL, Collins FH, Duffy PE. Malaria: progress, perils, and prospects for eradication. *J Clin Invest.* 2008; 118:1266–1276. [PubMed: 18382739]
4. Greenwood BM. Control to elimination: implications for malaria research. *Trends Parasitol.* 2008; 24:449–454. [PubMed: 18760671]
5. Ballou WR. The development of the RTS,S malaria vaccine candidate: challenges and lessons. *Parasite Immunol.* 2009; 31:492–500. [PubMed: 19691554]
6. White NJ. Antimalarial drug resistance. *J Clin Invest.* 2004; 113:1084–1092. [PubMed: 15085184]
7. Eastman RT, Fidock DA. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. *Nat Rev Microbiol.* 2009; 7:864–874. [PubMed: 19881520]
8. Dondorp AM, Yeung S, White L, Nguon C, Day NP, Socheat D, von Seidlein L. Artemisinin resistance: current status and scenarios for containment. *Nat Rev Microbiol.* 2010; 8:272–280. [PubMed: 20208550]
9. Mackinnon MJ, Marsh K. The selection landscape of malaria parasites. *Science.* 2010; 328:866–871. [PubMed: 20466925]
10. Olliaro P, Wells TN. The global portfolio of new antimalarial medicines under development. *Clin Pharmacol Ther.* 2009; 85:584–595. [PubMed: 19404247]
11. Wells TN, Alonso PL, Gutteridge WE. New medicines to improve control and contribute to the eradication of malaria. *Nat Rev Drug Discov.* 2009; 8:879–891. [PubMed: 19834482]
12. Craft JC. Challenges facing drug development for malaria. *Curr Opin Microbiol.* 2008; 11:428–433. [PubMed: 18824124]
13. Guiguemde WA, Shelat AA, Bouck D, Duffy S, Crowther GJ, Davis PH, Smithson DC, Connelly M, Clark J, Zhu F, Jimenez-Diaz MB, Martinez MS, Wilson EB, Tripathi AK, Gut J, Sharlow ER, Bathurst I, El Mazouni F, Fowble JW, Forquer I, McGinley PL, Castro S, Angulo-Barturen I, Ferrer S, Rosenthal PJ, Derisi JL, Sullivan DJ, Lazo JS, Roos DS, Riscoe MK, Phillips MA, Rathod PK, Van Voorhis WC, Avery VM, Guy RK. Chemical genetics of *Plasmodium falciparum*. *Nature.* 2010; 465:311–315. [PubMed: 20485428]
14. Gamo FJ, Sanz LM, Vidal J, de Cozar C, Alvarez E, Lavandera JL, Vanderwall DE, Green DV, Kumar V, Hasan S, Brown JR, Peishoff CE, Cardon LR, Garcia-Bustos JF. Thousands of chemical starting points for antimalarial lead identification. *Nature.* 2010; 465:305–310. [PubMed: 20485427]
15. Phillips MA, Rathod PK. Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy. *Infect Disord Drug Targets.* 2010; 10:226–239. [PubMed: 20334617]
16. Gujjar R, Marwaha A, El Mazouni F, White J, White KL, Creason S, Shackleford DM, Baldwin J, Charman WN, Buckner FS, Charman S, Rathod PK, Phillips MA. Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. *J Med Chem.* 2009; 52:1864–1872. [PubMed: 19296651]
17. Phillips MA, Gujjar R, Malmquist NA, White J, El Mazouni F, Baldwin J, Rathod PK. Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite, *Plasmodium falciparum*. *J Med Chem.* 2008; 51:3649–3653. [PubMed: 18522386]

18. Baldwin J, Michnoff CH, Malmquist NA, White J, Roth MG, Rathod PK, Phillips MA. High-throughput screening for potent and selective inhibitors of *Plasmodium falciparum* dihydroorotate dehydrogenase. *J Biol Chem*. 2005; 280:21847–21853. [PubMed: 15795226]
19. Gujjar R, El Mazouni F, White KL, White J, Creason S, Shackleford DM, Deng X, Charman WN, Bathurst I, Burrows J, Floyd DM, Matthews D, Buckner FS, Charman SA, Phillips MA, Rathod PK. Lead-optimization of aryl and aralkyl amine based triazolopyrimidine inhibitors of *Plasmodium falciparum* dihydroorotate dehydrogenase with anti-malarial activity in mice. *J Med Chem*. 2011; 54:3935–3949. [PubMed: 21517059]
20. Patel V, Booker M, Kramer M, Ross L, Celatka CA, Kennedy LM, Dvorin JD, Duraisingh MT, Sliz P, Wirth DF, Clardy J. Identification and characterization of small molecule inhibitors of *Plasmodium falciparum* dihydroorotate dehydrogenase. *J Biol Chem*. 2008; 283:35078–35085. [PubMed: 18842591]
21. Booker ML, Bastos CM, Kramer ML, Barker RH jr, Skerlj R, Bir Sdhu A, Deng X, Celatka C, Cortese JF, Guerrero Bravo JE, Krespo Llado KN, Serrano AE, Angulo-Barturen I, Belén Jiménez-Díaz M, Viera S, Garuti H, Wittlin S, Papastogiannidis P, Lin J, Janse CJ, Khan SM, Duraisingh M, Coleman B, Goldsmith EJ, Phillips MA, Munoz B, Wirth DF, Klinger JD, Wiegand R, Sybertz E. Novel inhibitors of *Plasmodium falciparum* dihydroorotate dehydrogenase with anti-malarial activity in the mouse model. *J Biol Chem*. 2010; 285:33054–33064. [PubMed: 20702404]
22. Deng X, Gujjar R, El Mazouni F, Kaminsky W, Malmquist NA, Goldsmith EJ, Rathod PK, Phillips MA. Structural plasticity of malaria dihydroorotate dehydrogenase allows selective binding of diverse chemical scaffolds. *J Biol Chem*. 2009; 284:26999–27009. [PubMed: 19640844]
23. Erkin AV, Krutikov VI. Formation, structure and heterocyclization of aminoguanidine and ethyl acetoacetate condensation products. *Russ J Gral Chem*. 2009; 79:1204–1209.
24. Allen CFH, Beilfuss HR, Burness DM, Reynolds GA, Tinker JF, VanAllan JA. *J Org Chem*. 1959; 24:787–793.
25. Yamashkin SA, Kucherenko NY, Yurovskaya MA. *Khim Geterotsikl Soedin*. 1997:579–597.
26. Painter HJ, Morrissey JM, Mather MW, Vaidya AB. Specific role of mitochondrial electron transport in blood-stage *Plasmodium falciparum*. *Nature*. 2007; 446:88–91. [PubMed: 17330044]
27. Ganesan SM, Morrissey JM, Ke H, Painter HJ, Laroia K, Phillips MA, Rathod PK, Mather MW, Vaidya AB. Yeast dihydroorotate dehydrogenase as a new selectable marker for *Plasmodium falciparum* transfection. *Mol Biochem Parasitol*. 2011; 177:29–34. [PubMed: 21251930]
28. Jimenez-Diaz MB, Mulet T, Viera S, Gomez V, Garuti H, Ibanez J, Alvarez-Doval A, Shultz LD, Martinez A, Gargallo-Viola D, Angulo-Barturen I. Improved murine model of malaria using *Plasmodium falciparum* competent strains and non-myelodepleted NOD-scid IL2R γ null mice engrafted with human erythrocytes. *Antimicrob Agents Chemother*. 2009; 53:4533–4536. [PubMed: 19596869]
29. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. *Methods in enzymology*. 1997; 276:307–326.
30. McCoy AJ. Solving structures of protein complexes by molecular replacement with Phaser. *Acta Crystallogr D Biol Crystallogr*. 2007; 63:32–41. [PubMed: 17164524]
31. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. *Acta Crystallogr D Biol Crystallogr*. 2004; 60:2126–2132. [PubMed: 15572765]
32. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. *Acta Crystallogr D Biol Crystallogr*. 1997; 53:240–255. [PubMed: 15299926]
33. Kleywegt GJ, Jones TA. A super position. *CCP4/ESF-EACBM Newsletter on Protein Crystallography*. 1994; 31:9–14.
34. Holm L, Park J. DaliLite workbench for protein structure comparison. *Bioinformatics*. 2000; 16:566–567. [PubMed: 10980157]
35. Desjardins RE, Canfield CJ, Haynes JD, Chulay JD. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. *Antimicrob Agents Chemother*. 1979; 16:710–718. [PubMed: 394674]

36. Jiang L, Lee P, White J, Rathod P. Potent and selective activity of a combination of thymidine and 1843U89, a folate-based thymidylate synthase inhibitor, against *Plasmodium falciparum*. *Antimicrob agents and chemotherapy*. 2000; 44:1047–1050.
37. Bevan CD, Lloyd RS. A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. *Anal Chem*. 2000; 72:1781–1787. [PubMed: 10784141]
38. Valko K, Nunhuck S, Bevan C, Abraham MH, Reynolds DP. Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol/water and immobilized artificial membrane lipophilicity. *J Pharm Sci*. 2003; 92:2236–2248. [PubMed: 14603509]
39. Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. *Drug Metab Dispos*. 1999; 27:1350–1359. [PubMed: 10534321]
40. Davies B, Morris T. Physiological parameters in laboratory animal and humans. *Pharm Res*. 1993; 10:1093–1095. [PubMed: 8378254]
41. Angulo-Barturen I, Jimenez-Diaz MB, Mulet T, Rullas J, Herreros E, Ferrer S, Jimenez E, Mendoza A, Regadera J, Rosenthal PJ, Bathurst I, Pompliano DL, Gomez de las Heras F, Gargallo-Viola D. A murine model of *falciparum*-malaria by in vivo selection of competent strains in non-myelodepleted mice engrafted with human erythrocytes. *PLoS One*. 2008; 3:e2252. [PubMed: 18493601]
42. Phillips, MA.; Rathod, PK.; Charman, SA.; Floyd, D.; Burrows, J.; Matthews, G.; Marwaha, A.; Gujar, R.; Coteron-Lopez, J. Antimalarial agents that are inhibitors of dihydroorotate dehydrogenase. WO 2011/041304. 2011. PCT/US2010/050532, 4/07/11

Fig. 1.
Structures of select triazolopyrimidines

Fig. 2.

P. falciparum *in vitro* growth curves and genetic rescue with yeast DHODH for **38**. Data were collected in human serum and were fitted to the 4 parameter dose response equation in Graphpad Prism to obtain EC_{50} values. **38** (*P. falciparum* 3D7; EC_{50} = 0.019 μ M (0.016–0.022)); **3** (*P. falciparum* 3D7; EC_{50} = 1.1 μ M (1.1–1.2)); **38** (*P. falciparum* D10; EC_{50} = 0.086 μ M (0.066–0.11)); **38** (*P. falciparum* D10 transfected with yeast DHODH; EC_{50} >20 μ M). Values in parenthesis represent the 95% confidence interval. Addition of proguanil did not restore sensitivity to the D10_ yeast DHODH cell line (EC_{50} >20 μ M; data not shown).

Figure 3A

Figure 3B

Fig. 3. X-ray structure determination of *PfDHODH* in complex with **37**. A. Structural alignment of *PfDHODH*_{Δ384-413}-**37** (green) in comparison to *PfDHODH* bound with **2** (pdb 3I6R) (pink). Residues within 4Å of the bound inhibitor are displayed. L-ornithine and the FMN cofactor

are also displayed. B. Van der Waals surface representation of *Pf*DHODH bound with **37**. The enzyme surface is shown in pink, and orotate, FMN and **37** are shown in green as sticks. Structures were displayed using PyMol.

Fig. 4. Pharmacokinetic analysis of A) **38** and B) **37** after oral dosing in mice (n=1 mouse per time point). Plots represent plasma concentration versus time after a single dose. Dose levels and route are shown in the graph legend.

Fig. 5. Pharmacokinetic analysis of A) **38** and B) **37** after oral (PO) or IV dosing in rats (n=2 rats per dose route). Plots represent plasma concentration versus time after a single dose. Dose levels and route are shown in the graph legend.

Fig. 6. Efficacy of **38** in SCID mice infected with *P. falciparum* after oral dosing. Mice were infected with parasites on day zero and a single oral dose/day was given on days 3, 4, 5 and 6. The limit of detection of the assay is 0.01% parasitemia. Dose levels are shown in the graph legend.

Scheme 1.

Synthesis of the triazolopyrimidine compounds **11–55, 100**

General conditions. (i) EtOH, reflux 5 h, over night at RT; (ii) **9a–9g, 9j, 9k, 9m–9o**: 1,4 dioxane, DMF, requisite acid chloride, reflux O/N or **9h, 9i**: NaEtO, EtOH, 80°C, 30 min, appropriate difluoropropanoate or difluorobutanoate, 30 min, RT, (1.5 – 3) h, 80°C; (R defined in Table 1) (iii) **9l, 9p** AcOH, reflux, 8 h; (iv) reflux in POCl₃; (v) requisite aniline (R₁ and R₂ defined in Table 1), EtOH, reflux 1–3 h.

Scheme 2.

Synthesis of the triazolopyrimidine compounds **66–84**

General conditions. (i) POCl_3 , reflux, 10 h; (ii) requisite aniline (R_1 and R_2 defined in Table 1), EtOH, RT; (iii) AcOH, RT, H_2O_2 , Na_2WO_4 (cat), 50°C ; (iv) R_3OH (R_3 defined in Table 1), NaH, THF, microwave, 120°C , (0.5 – 1) h

Scheme 3. Synthesis of triazolopyrimidines **89 – 97**

Reagents and conditions. (i) amine in MeOH or THF, MW, 120°C, 30–45 min, (40 – 70%).

Scheme 4. Synthesis of triazolopyrimidines **98**, **99** and **101**

Reagents and conditions. (i) MeOH, H-cube hydrogenation, 50°C, 10% Pd/C, (11 – 12%)

Table 1

Structure activity relationships of the triazolopyrimidine compounds

Cpd	Name	R	R1	R2	IC ₅₀ (μM) <i>Pf</i> /DHODH	IC ₅₀ (μM) <i>Pf</i> /DHODH	IC ₅₀ (μM) <i>h</i> /DHODH	EC ₅₀ (μM) <i>Pf</i> 3D7 cells
2	DSM74 ^a	H	CF ₃	H	0.28	0.38	>100	0.34
3	DSM161 ^b	H	SF ₅	H	0.13	0.28	>100	1.3, 0.18*
5	DSM89	H	Cl	H	1.6	5.7	>100	12
6	DSM75	H	H	Cl	1.4	31	>100	8.5
11	DSM271	CH ₂ CH ₃	Cl	H	0.28	2.3	ND	0.79
12	DSM272	CH ₂ CH ₃	H	Cl	0.24	ND	ND	3.3
13	DSM280	CH ₂ CH ₃	CF ₃	H	0.087	0.76	>100	0.058
14	DSM281	CH ₂ CH ₃	SF ₅	H	0.15	1.4	>100	0.1
15	DSM309	iso-Pr	Cl	H	0.33	2.1		0.85
16	DSM308	iso-Pr	H	Cl	0.12	0.57		1.1
17	DSM307	iso-Pr	CF ₃	H	0.11	4.5	>100	0.098
18	DSM314	iso-Pr	SF ₅	H	0.10	3.8	>100	0.42
19	DSM313	iso-Bu	Cl	H	>10	ND	ND	ND
20	DSM312	iso-Bu	H	Cl	>10	ND	ND	ND

Cpd	Name	R	R1	R2	IC ₅₀ (μM) <i>Pf</i> DHODH	IC ₅₀ (μM) <i>Pb</i> DHODH	IC ₅₀ (μM) <i>h</i> DHODH	EC ₅₀ (μM) <i>Pf</i> 3D7 cells
	21	DSM311	iso-Bu	CF ₃	H	2.0	ND	ND	ND
	22	DSM310	iso-Bu	SF ₅	H	>10	ND	ND	ND
	23	DSM357	tert-Bu	CF ₃	H	0.46	15	>100	0.29
	24	DSM358	tert-Bu	SF ₅	H	0.55	16	>100	2.3
	25	DSM356	sec-Bu	CF ₃	H	0.38	4.6	>100	0.27
	26	DSM355	sec-Bu	SF ₅	H	0.33	4.5	>100	0.51
	27	DSM325	cycloPr	Cl	H	0.88	2.8	>100	6.8
	28	DSM324	cycloPr	H	Cl	0.82	1.7	>100	ND
	29	DSM322	cycloPr	CF ₃	H	0.14	2.6	>100	0.15
	30	DSM323	cycloPr	SF ₅	H	0.093	2.0	>100	0.50
	31	DSM321	CH ₂ cycloPr	Cl	H	12	ND	ND	ND
	32	DSM320	CH ₂ cycloPr	H	Cl	>10	ND	ND	ND
	33	DSM318	CH ₂ cycloPr	CF ₃	H	1.7	ND	ND	3.4
	34	DSM319	CH ₂ cycloPr	SF ₅	H	5.7	ND	ND	>10
	35	DSM254	CF ₂ CH ₃	Cl	H	0.038	1.7	>100	0.050
	36	DSM266	CF ₂ CH ₃	H	Cl	0.054	ND	ND	0.13
	37	DSM267	CF ₂ CH ₃	CF ₃	H	0.038 ^c	2.4	>100	0.010 ^e /0.0062 [*]

Cpd	Name	R	R1	R2	IC ₅₀ (μM) <i>Pf</i> DHODH	IC ₅₀ (μM) <i>Pb</i> DHODH	IC ₅₀ (μM) <i>h</i> DHODH	EC ₅₀ (μM) <i>Pf</i> 3D7 cells
38	DSM265	CF ₂ CH ₃	SF ₅	H	0.033 ^d	2.5	>100	0.046/0.0078*
39	DSM329	CF ₂ CH ₂ CH ₃	Cl	H	0.034	1.8	>100	0.094
40	DSM328	CF ₂ CH ₂ CH ₃	H	Cl	0.030	1.4	>100	1.2
41	DSM326	CF ₂ CH ₂ CH ₃	CF ₃	H	0.019	2.5	>100	0.045
42	DSM327	CF ₂ CH ₂ CH ₃	SF ₅	H	0.075	4.7	>100	0.55
43	DSM195	CF ₃	CF ₃	H	0.035	1.3	>100	0.073
44	DSM196	CF ₃	SF ₅	H	0.030	2.5	41	0.14
48	DSM299	CH ₂ OCH ₃	Cl	H	2.2	ND	ND	ND
49	DSM300	CH ₂ OCH ₃	H	Cl	1.7	ND	ND	ND
50	DSM305	CH ₂ OCH ₃	CF ₃	H	0.41	5.5	ND	1.0
51	DSM306	CH ₂ OCH ₃	SF ₅	H	0.39	3.3	ND	2.1
52	DSM301	CH ₂ CH ₂ OCH ₃	Cl	H	>10	ND	ND	ND
53	DSM302	CH ₂ CH ₂ OCH ₃	H	Cl	>10	ND	ND	ND
54	DSM303	CH ₂ CH ₂ OCH ₃	CF ₃	H	2.5	ND	ND	4.2
55	DSM304	CH ₂ CH ₂ OCH ₃	SF ₅	H	2.5	ND	ND	5.0
58	DSM257	SCH ₃	Cl	H	0.030	ND	ND	0.15

Cpd	Name	R	R1	R2	IC ₅₀ (μM) <i>Pf</i> DHODH	IC ₅₀ (μM) <i>Pb</i> DHODH	IC ₅₀ (μM) <i>h</i> DHODH	EC ₅₀ (μM) <i>Pf</i> 3D7 cells
59	DSM258	SCH ₃	H	Cl	0.026	ND	ND	0.15
60	DSM261	SCH ₃	CF ₃	H	0.036	4.8	ND	0.0084
61	DSM262	SCH ₃	SF ₅	H	0.030	>10	ND	0.032
62	DSM259	SO ₂ CH ₃	Cl	H	0.045	ND	ND	1.4
63	DSM260	SO ₂ CH ₃	H	Cl	0.16	ND	ND	>2.5
64	DSM263	SO ₂ CH ₃	CF ₃	H	0.090	ND	ND	0.17
65	DSM264	SO ₂ CH ₃	SF ₅	H	0.11	ND	ND	2.0
66	DSM227	OCH ₃	H	Cl	0.50	1.3	ND	0.98
67	DSM241	OCH ₃	Cl	H	0.46	1.2	ND	0.59
68	DSM245	OCH ₂ CH ₃	H	Cl	0.40	1.9	>100	4.4
69	DSM246	OCH ₂ CH ₃	Cl	H	0.27	1.6	>100	1.3
70	DSM293	OCH ₂ CH ₃	CF ₃	H	0.056	2.7	>100	0.058
71	DSM294	OCH ₂ CH ₃	SF ₅	H	0.057	0.47	>100	0.10
72	DSM298	OCH ₂ CH ₂ OCH ₃	Cl	H	>10	ND	ND	ND
73	DSM315	OCH ₂ CH ₂ OCH ₃	H	Cl	4.9	>10	ND	ND
74	DSM274	O(CH ₂) ₂ NHCH ₃	Cl	H	>10	ND	ND	ND

Cpd	Name	R	R1	R2	IC ₅₀ (μM) <i>Pf</i> DHODH	IC ₅₀ (μM) <i>Pb</i> DHODH	IC ₅₀ (μM) <i>h</i> DHODH	EC ₅₀ (μM) <i>Pf</i> 3D7 cells
75	DSM273	O(CH ₂) ₂ NHCH ₃	H	Cl	>10	ND	ND	ND
76	DSM275	O(CH ₂) ₂ NHCH ₃	CF ₃	H	>10	ND	ND	ND
77	DSM276	O(CH ₂) ₂ NHCH ₃	SF ₅	H	>10	ND	ND	ND
78	DSM287	O(CH ₂) ₂ N(CH ₃) ₂	Cl	H	>10	ND	ND	ND
79	DSM285	O(CH ₂) ₂ N(CH ₃) ₂	H	Cl	>10	ND	ND	ND
80	DSM289	O(CH ₂) ₂ N(CH ₃) ₂	CF ₃	H	>10	ND	ND	ND
81	DSM291	O(CH ₂) ₂ N(CH ₃) ₂	SF ₅	H	>10	ND	ND	ND
82	DSM295	O(CH ₂) ₂ NH ₂	H	Cl	>10	ND	ND	ND
83	DSM296	O(CH ₂) ₂ NH ₂	CF ₃	H	>10	ND	ND	ND
84	DSM297	O(CH ₂) ₂ NH ₂	Cl	H	>10	ND	ND	ND
85	DSM288	=O	Cl	H	>10	ND	ND	ND
86	DSM286	=O	H	Cl	>10	ND	ND	ND
89	DSM253	(CH ₂) ₂ NHCH ₃	Cl	H	>10	ND	ND	>2.5
90	DSM277	CH ₂ NH ₂	Cl	H	>10	ND	ND	ND
91	DSM278	CH ₂ NHCH ₃	Cl	H	>10	ND	ND	ND
92	DSM279	CH ₂ NH(CH ₃) ₂	Cl	H	>10	ND	ND	ND
93	DSM256	(CH ₂) ₂ NHCH ₃	H	Cl	>10	ND	ND	>2.5

Cpd	Name	R	R1	R2	IC ₅₀ (μM) <i>Pf</i> DHODH	IC ₅₀ (μM) <i>Pb</i> DHODH	IC ₅₀ (μM) <i>h</i> DHODH	EC ₅₀ (μM) <i>Pf</i> 3D7 cells
94	DSM282	CH ₂ NH(CH ₃) ₂	H	Cl	>10	ND	ND	ND
95	DSM283	CH ₂ NH ₂	H	Cl	>10	ND	ND	ND
96	DSM284	CH ₂ NHCH ₃	H	Cl	>10	ND	ND	ND
97	DSM292	CH ₂ CH ₂ NH ₂	Cl	H	>10	ND	ND	ND
98	DSM268	CH ₂ OH	Cl	H	5.3	ND	ND	>2.5
99	DSM255	CH ₂ OH	H	Cl	6.1	ND	ND	>10
101	DSM317	CH ₂ CH ₂ OH	CF ₃	H	0.93	ND	ND	0.48

^{a,b} previously reported compounds^{16, 19}.

Values were determined based on triplicate data points at each test concentration. Additionally, ^{c,d} average of n=4 independent experiments on different synthetic batches (std dev = ^c0.012, ^d0.0095);

^{e,f} average of n=6 independent experiments on different synthetic batches (std dev = ^e0.0045, ^f0.013). *P. falciparum* 3D7 results – data collected in media containing human serum, except * where Albumax was used instead. ND, not determined.

Table 2

Physicochemical properties and *in vitro* metabolism

Cpd	Log D _{pH 7.4}	Aqueous Solubility pH 6.5 (μM)	^c Human plasma protein binding %	CL _{int} human/mouse (μL/min/mg protein)	E _h Human/Mouse
2	2.5	21–43	86.9 ^c	8/ND	0.29/ND
3	3.0	71–142	95.4 ^c	<5/<6	0.20/0.20
6	2.4	ND	ND	38.2/ND	0.68/ND
11	2.8	170 – 350	86.1 ^c	12.8/63.1	0.42/0.73
12	2.8	170 – 350	86.7 ^c	78.3/125.4	0.81/0.85
13	3.0	39 – 78	87.5 ^c	<5/14.4	<0.2/0.39
14	3.3	34 – 66	96.4 ^c	<5/16.7	<0.2/0.42
15	3.2	83 – 170	84.9 ^c	14.1/157.7	0.44/0.87
29	3.3	38 – 75	92.8 ^c	<5/8.6	<0.2/0.27
30	3.5	16 – 32	97.7 ^c	<5/12.6	<0.2/0.36
35	3.0	77 – 150	87.9 ^c	16/62.8	0.47/0.73
36	3.0	77 – 150	88.2 ^c	44.4/72.2	0.71/0.76
37	3.3	70 – 140	90.4 ^c ; 98.8 ^d	<5/10.1	<0.2/0.31
38	3.6	30 – 60	97.4 ^c ; 99.9 ^d	<5/8.1	<0.2/0.26
41	3.6	17 – 34	93.2 ^c	<5/6.5	<0.2/0.22
42	3.9	15 – 30	97.7 ^c	<5/6.7	<0.2/0.23
43	ND	ND	ND	<5/<6	<0.2/<0.2
44	3.7	30 – 60	ND	<5/<6	<0.2/<0.2
50	2.5	150 – 300	75.6 ^c	6.7/13.3	0.27/0.37
51	2.8	63 – 130	91.7 ^c	5.6/14.3	0.24/0.38
54	2.7	71 – 140	73.7 ^c	9.0/14.3	0.34/0.38
55	3.0	31 – 62	87.7 ^c	11.5/14.1	0.39/0.38
60	3.2	19 – 38	91.8 ^c	18.7/76.9	0.51/0.77

Cpd	Log D _{pH 7.4}	Aqueous Solubility pH 6.5 (μM)	^c Human plasma protein binding%	CL _{int} human/mouse (μL/min/mg protein)	E _h Human/Mouse
61	3.5	7.8 – 15	97.7 ^c	22.4/107.5	0.56/0.82
70	3.1	19 – 37	92.4 ^c	7.0/14.4	0.28/0.38
71	3.4	4 – 8	97.7 ^c	<5/11.3	<0.2/0.33
101	2.2	19 – 37	67.0 ^c	<5/6.9	<0.2/0.23

^{a,b} previously reported compounds – data provided for comparison^{16, 19}.

^c chromatographic method.

^d ultracentrifugation method. E_h <0.3 represents low predicted metabolism, E_h 0.4 – 0.7 moderate predicted metabolism and E_h >0.8 high predicted metabolism. ND, not determined.

Table 3Comparison of *P. falciparum* cell lines and mammalian cytotoxicity data

Compound	38 EC ₅₀ (μM)	37 EC ₅₀ (μM)
<i>P. falciparum</i> 3D7 (μM)	0.043 (0.034 – 0.055)	0.013 (0.012 – 0.014)
<i>P. falciparum</i> D6 (μM)	0.022 (0.014 – 0.034)	0.012 (0.011 – 0.013)
<i>P. falciparum</i> K1 (μM)	0.057 (0.048 – 0.068)	0.016 (0.014 – 0.017)
<i>P. falciparum</i> HB3 (μM)	0.027 (23 – 31)	0.0079 (0.0072 – 0.0086)
<i>P. falciparum</i> Dd2 (μM)	0.057 (0.041 – 0.079)	0.013 (0.012 – 0.014)
<i>P. falciparum</i> TM90C2B	0.015 (0.013 – 0.018)	0.0046 (0.0013 – 0.016)
<i>P. falciparum</i> TM90C2A	0.031 (0.023 – 0.033)	0.0079 (0.0076 – 0.0081)
Mouse L1210	>50	>50
Human Hep G2 (μM)	>50	>50

Additional *P. falciparum* strains that were tested include drug sensitive strains (D6, HB3 and NF54), chloroquine resistant strains (Dd2) chloroquine and pyrimethamine resistant (K1), and atovoquone resistant strains (TM90C2B and TM90C2A). Data were collect on strain 3D7 as a comparator. Data were collected in triplicate and values in parenthesis represent the 95% confidence interval. Data were collected using human serum containing media.

Table 4*In vivo* pharmacokinetic data for key triazolopyrimidines in mice

A. Compounds 37 and 38 evaluated after a single oral dose of 0.4, 2, 10 or 50 mg/kg		
Parameter	37	38
p.o. Dose (mg/kg)	0.4, 2, 10, 50	0.4, 2, 10 ^a , 50
t _{1/2} (h)	2.1, 1.9, 1.6, cnc	4.1, 3.5, 2.5, 3.2
C _{max} (μM)	0.20, 1.85, 9.86, 57	0.06, 0.44, 3.1, 9.53
T _{max} (h)	0.5, 1, 4, 2	0.5, 1.0, 1.5, 2.0
Time _{C>1 μM} (h)	0, 6, 14, 14	0, 0, 8, 6
Plasma AUC _{0-inf} (μM*min);	40, 569, 4207, 14815 ^b	27, 163, 1357, 2028
Plasma protein binding (%)	97.4	99.6

B. Compounds 13, 41, 70 and 71 after a single oral dose of 10 or 20 mg/kg				
Parameter	13	41	70	71
p.o. Dose (mg/kg)	20	10	20	20
t _{1/2} (h)	8.4	3.1	1.4	2.7
C _{max} (μM)	12.6	3.5	5.8	1.1
T _{max} (min)	60	30	60	60
Time _{C>1 μM} (h)	5	4	6	3
AUC _{0-inf} (μM*min)	1624	652	1241	608

^a values at 10 mg/kg are the average for 2 independent experiments^b AUC_{0-48 h}

cnc, could not calculate

Table 5*In vivo* pharmacokinetic properties for **37** and **38** in rats (average of n=2 per dose level)

Parameter	37	38
i.v. Dose (mg/kg)	1; 4.5	0.9; 2.6
Clearance (ml/min/kg)	23.2; 12.6	3.6; 6
t _{1/2} (hr)	6.1; 3.8 *	10.1; 12.6
Volume of distribution (L/kg)	3.3; 2.9	2.9; 5.9
p.o. Dose (mg/kg)	2.0; 21.2	2.1; 18.8; 46.7
T _{max} (min)	60; 195	195; 420; 1020
C _{max} (μM)	0.9; 11.4	0.75; 3.9; 6.4
Bioavailability (F%)	97; >100	66; 57; 61
t _{1/2} (hr)	6; 17	11.6; 15.5; 27.9
AUC _{0-inf} (μM*min)	233; 20492	929; 7292; 19305
Blood:plasma	0.7 – 0.8	0.7 – 0.8
Plasma protein binding (%)	94.2	97.3

Table 6

In vivo Efficacy and pharmacokinetic properties in the SCID mouse *P. falciparum* model after oral dosing (average of n=3 mice per compound)

	4	37	38
ED ₅₀ /ED ₉₀ (mg/kg)	19/59	9.6/26	2.8/8.1
p.o. Dose (mg/kg)	10	5.7	7.0
Blood AUC _(0-t) # uninfected/infected (μM*min)	3848/3173	2521/2740	3469/3427
C _{max} uninfected/infected (μM)	8.5/8.2	6.3/6.3	6.1/5.3
T _{max} uninfected/infected (h)	2.0/3.3	2.7/1.7	4/6.7

ED₅₀ for chloroquine control 3.2 mg/kg. #t=10h after dosing for **4** and **37** and 24 h after dosing for **38**. This time point represents the last time point where compounds were detectable in whole blood of animals.